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Highlights 
 
 Astrocytes are crucial players in the developing and adult CNS in health and disease. 
 Astrocytes play a key role in the balance of regenerative and degenerative functions. 
 Differentiation, identity and functions of astrocytes are regulated through transcriptional 
and epigenetic programs.  
 The capacity of astrocytes to become reactive or be reprogrammed provides promise for 
endogenous brain repair strategies. 
 Deregulation of astrocytic transcriptional or epigenetic mechanisms may contribute to 
neurological disorders, such as neurodegenerative diseases and brain cancers. 
 Molecular mechanisms underlying astrocytic identity may offer novel therapeutic 
opportunities.  
 
 
Abstract 
 
Astrocytes play a significant role in coordinating neural development and provide critical 
support for the function of the CNS. They possess important adaptation capacities that range from 
their transition towards reactive astrocytes to their ability to undergo reprogramming, thereby 
revealing their potential to retain latent features of neural progenitor cells. We propose that the 
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mechanisms underlying reactive astrogliosis or astrocyte reprogramming provide an opportunity 
for initiating neuronal regeneration, a process that is notably reduced in the mammalian nervous 
system throughout evolution. Conversely, this plasticity may also affect normal astrocytic 
functions resulting in pathologies ranging from neurodevelopmental disorders to 
neurodegenerative diseases and brain tumors. We postulate that epigenetic mechanisms linking 
extrinsic cues and intrinsic transcriptional programs are key factors to maintain astrocyte identity 
and function, and critically, to control the balance of regenerative and degenerative activity. Here, 
we will review the main evidences supporting this concept. We propose that unravelling the 
epigenetic and transcriptional mechanisms underlying the acquisition of astrocyte identity and 
plasticity, as well as understanding how these processes are modulated by the local 
microenvironment under specific threatening or pathological conditions, may pave the way to new 
therapeutic avenues for several neurological disorders including neurodegenerative diseases and 
brain tumors of astrocytic lineage. 
 
 
Contents 
 
1. Introduction 
2. Epigenetic modifications: basic mechanisms and their role in CNS development 
      2.1 DNA methylation 
      2.2 Histone modifications 
      2.3 Non-coding RNAs 
3. Differentiation of neural stem cells into astrocytes 
3.1 Key extracellular signals and transcriptional activators 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
4 
 
 3.1.1 The Notch pathway 
 3.1.2 The JAK-STAT signaling pathway 
 3.1.3 The BMP pathway 
3.2 Importance of DNA methylation in the acquisition of the astrocytic fate 
3.3 Histone modifications associated to astrocytic differentiation 
3.4 Essential miRNAs for the generation of astrocytes 
4. Spinal cord/traumatic brain injuries and neurodegenerative disorders 
      4.1 The molecular repertoire of reactive astrocytes 
 4.1.1 Reactive astrocytes in spinal cord and traumatic brain injuries 
 4.1.2 Reactive astrocytes in neurodegenerative diseases 
4.1.3 Heterogeneity of reactive astrocytes 
      4.2 MiRNAs’ functioning in the process of astrocyte reactivity 
5. Astrocyte plasticity: dedifferentiation and reprogramming 
      5.1 Influence of external stimuli 
      5.2 Effects of genetic manipulation 
6. Brain tumors of astrocytic lineage 
      6.1 The importance of IDH genes 
      6.2 The methylation phenotype of brain tumors 
      6.3 Histone changes linked to Glioblastoma 
      6.4 MiRNAs associated with Glioblastoma      
7. Conclusions and perspectives 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
5 
 
Abbreviations 
 
5hmC= 5-hydroxymethylcytosine 
5mC= 5-methylcytosine 
Aβ= amyloid β 
AD= Alzheimer’s disease 
ASCL1= Achaete-Scute Family BHLH Transcription Factor 1 
BBB= blood-brain barrier 
BDNF= brain-derived neurotrophic factor  
BHLH= basic helix-loop-helix  
BMP= bone morphogenetic protein 
CSCs= cancer stem-like cells 
CNS= central nervous system 
CNTF= ciliary neurotrophic factor 
Coup-tfI and Coup-tfII= Chicken ovalbumin upstream promoter-transcription factors I and II 
DNMT1= DNA methyltransferase 1   
E= embryonic day  
EZH2= Enhancer of zeste homolog 2 gene 
ESET= ERG-associated protein with SET domain 
FGF2= fibroblast growth factor 
GASC1= gene amplified in squamous cell carcinoma 1 
GBM= Glioblastoma 
G-CIMP= glioma-CpG island methylator phenotype 
GFAP= glial fibrillary acidic protein 
GSC= GBM cancer stem-like cells 
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H1= Histone 1 
H2A= Histone 2A 
H2B= Histone 2B 
H3= Histone 3 
H4= Histone 4 
H3K4me= methylation of Lysine 4 of Histone 3 
H3K9me= methylation of Lysine 9 of Histone 3 
H3K4me2= dimethylation of Lysine 4 of Histone 3 
H3K9me2= dimethylation of Lysine 9 of Histone 3 
H3K9me3= trimethylation of Lysine 9 of Histone 3 
H3K27me3= trimethylation of Lysine 27 of Histone 3 
H3K36me3= trimethylation of Lysine 36 of Histone 3 
H4K20me= methylation of Lysine 20 of Histone 4 
HDACs= histone deacetylases 
HDAC3= histone deacetylase 3 
hESCs= human embryonic stem cells 
HMT= histone methyltransferase 
IDH1= isocitrate dehydrogenase 1 
IDH2= isocitrate dehydrogenase 2 
IFN-γ= interferon-gamma  
IL-6= interleukin 6 
JAK= Janus kinase  
JNK= c-Jun N-terminal kinase 
KDM5A= lysine-specific demethylase 5A 
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LCN2= lipocalin 2 
LIF= leukemia inhibitory factor 
lncRNA= long non-coding RNA 
MAPK= Ras/mitogen-activated protein kinase 
MECP2= methyl CpG binding protein 2 
MGMT= DNA repair enzyme O6-methylguanine-DNA methyltransferase 
miRNAs= microRNAs 
MPTP= 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
NADPH= nicotinamide adenine dinucleotide phosphate 
ncRNA= non-coding RNA 
NFIA= nuclear factor I A-type 
NFIB= nuclear factor I B-type 
NF-κB= nuclear factor kappa-light-chain-enhancer of activated B cells  
NICD= Notch intracellular domain 
NSCs= neural stem cells 
RA= retinoic acid  
RARs= retinoic acid receptors   
RXRs= retinoid X receptors 
RBP-J= recombining binding protein suppressor of hairless 
SCI= spinal cord injury  
SHH= Sonic hedgehog 
STAT3= signal transducer and activator of transcription 3 
STAT/CBP= signal transducer and activator of transcription/CRE binding protein 
SVZ= subventricular zone 
TBI= traumatic brain injury 
TET= ten‐eleven translocation family of enzymes 
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TGF-β= transforming growth factor-beta 
TNF= tumor necrosis factor-alpha 
PD= Parkinson’s disease 
WNT1= wingless-type MMTV integration site1 
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1. Introduction 
 
  Astrocytes represent the most abundant cell population in the adult brain. As such, they 
are involved in several activities, ranging from regulating ion and fluid homeostasis, establishing 
and maintaining the blood-brain barrier (BBB) (Oberheim et al., 2006; Zhang and Barres, 2010)  
to providing neurons with nutrients and metabolites (Escartin et al., 2007; Pellerin et al., 2007). 
Further, they are involved in regulating synaptic transmission through the uptake of the 
neurotransmitter glutamate (Parpura et al., 1994), they interact with neurons as they actively 
participate  in the formation and functioning of neuronal synapses (Barres, 2008) and they 
communicate with them through calcium signals (Nedergaard, 1994). The active communication 
between astrocytes and neurons is involved in sleep homeostasis, breathing, circadian regulation 
and memory (McIver  Sally R. , 2013). Further, astrocytes promote the differentiation of 
oligodendrocyte progenitor cells into mature myelinating oligodendrocytes and support myelin 
maintenance (Domingues et al., 2016). 
Under CNS insults such as trauma, tumor, infection or neurodegeneration, astrocytes 
become activated, a process known as reactive astrogliosis, resulting in changes in their 
morphology and expression of their molecular repertoire (Pekny and Nilsson, 2005; Sofroniew, 
2009). Reactive astrocytes release pro- and anti-inflammatory cytokines, thus implying both 
beneficial and detrimental effects in a context-dependent manner. Under specific conditions, the 
consequence of the neuroinflammatory response following brain injury is the formation of the glial 
scar, mainly constituted by reactive astrocytes, which acts as a physical insulator to contain the 
lesioned area. In mammals, intriguingly, the glial scar acts as a negative regulator of neurogenesis 
and neurite outgrowth, in comparison to lower vertebrates, which are able to recruit glial 
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progenitors that undergo reactive neurogenesis and replace the neurons lost upon injury (Kroehne 
et al., 2011). Notably, reactive astrocytes exhibit endogenous NSC hallmarks such as self-renewal, 
multipotency and expression of immature markers. In the mouse cerebral cortex, only a subset of 
astrocytes are able to restore their proliferation capacity and enter a reprogramming mode, 
whereupon they are able to form neurospheres and generate neurons (with firing action potential), 
oligodendrocytes and astrocytes or be directly reprogrammed into neurons or neuroblasts in vivo 
(Bardehle et al., 2013; Gascon et al., 2017; Gotz et al., 2015; Niu et al., 2013). Could these 
terminally differentiated astrocytes be considered as immature or even as latent stem cells since 
they possess the capacity to re-enter a self-renewal process and, eventually, potentially a 
differentiation process and even acquire an alternate cell identity? It is possible that the 
mechanisms underlying reactive astrogliosis or astrocyte reprogramming may hold the secret of 
neuronal regeneration, a process that is lost during evolution of the mammalian CNS. 
The onset of astrogenesis relies upon extracellular signaling and intrinsic epigenetic 
modifications, such as DNA methylation and histone modifications. Disruption in any of these 
mechanisms causes abnormal astrocyte differentiation and leads to neurodevelopmental disorders 
(Molofsky et al., 2012; Sloan and Barres, 2014). The importance of astrocytes for neuronal 
integrity and survival is also prominent in the adult brain. Conditional ablation of astrocytes in 
adult mice results in neuronal loss and severe motor deficits (Schreiner et al., 2015). On the other 
hand, their contribution to neuroinflammation and the loss of normal homeostatic functions, may 
corroborate their implication in the onset and progression of neurodegenerative diseases, including 
Parkinson’s and Alzheimer’s diseases (PD and AD) (Niranjan, 2014). Brain cancer is another 
neurological disease where astrocytes are currently implicated both as tumor initiating cells and 
modulators of the tumor microenvironment (Ahmed et al., 2013). Supporting the notion that brain 
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tumors can arise from differentiated cells, transduction of murine astrocytes in vivo with oncogenic 
lentiviral vectors results in tumor formation. Mature astrocytes were shown to be able to 
dedifferentiate and gain expression of progenitor/stem cell markers or even transdifferentiate into 
neurons during tumorigenesis (Friedmann-Morvinski et al., 2012). Transformed astrocytes can be 
reprogrammed to re-acquire stem cell features, but also give rise to more malignant phenotypes, 
thereby generating a heterogeneous cell population within the malignant tumor (Friedmann-
Morvinski et al., 2012; Friedmann-Morvinski and Verma, 2014).  
Clearly, astrocytes are crucial players in the developing and adult CNS in both health and 
disease. Consequently, it is critical to elucidate the transcriptional and epigenetic mechanisms 
underlying acquisition of astrocyte identity and plasticity, as well as understanding how these 
processes are modulated under pathological conditions. The comprehension of these mechanisms 
will pave the way to novel therapeutic approaches aimed, for example, at restoring the homeostatic 
astrocytic functions in brain tumors or at enhancing their neurogenic properties in 
neurodegenerative diseases. This review focuses on those transcriptional and epigenetic 
mechanisms underlying the physiological differentiation and activation of astrocytes that 
contribute to our understanding of aberrant phenotypes identified under pathological conditions 
leading to neurological disorders. 
 
2. Epigenetic modifications: basic mechanisms and their role in CNS development 
 
Epigenetics generally refers to any heritable alteration occurring in a cell that has an 
immediate effect on gene expression, without modifying the DNA sequence. This includes DNA 
methylation and histone modifications, which are able to alter DNA accessibility and chromatin 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
12 
 
structure, and RNA-mediated epigenetic mechanisms that mainly act at the transcriptional and 
post-transcriptional level (Pavlou et al., 2017). 
 
2.1 DNA methylation 
 
DNA methylation entails the transfer of a methyl group from S-adenosyl methionine to the 
5’ position of cytosines, resulting in the formation of 5-methylcytosine (5mC) (Mehler, 2008). The 
methylation process occurs throughout the entire genome, although it is enriched in CpG islands. 
These sites are usually found in promoter regions and, therefore, methylation generally leads to 
reduced gene transcription. This is mediated by two mechanisms: i) DNA methylation prevents 
the association of DNA binding factors, such as transcription factors, to their cognate DNA 
sequence or ii) the methylated CpGs can recruit proteins involved in gene repression, such as co-
repressors (Figure 1) (Klose and Bird, 2006). 5mC can be converted to 5-hydroxymethylcytosine 
(5hmC) via an oxidation reaction catalyzed by the ten‐eleven translocation family of enzymes 
(TET). Although its function still remains enigmatic, 5hmC was thought to exist both as an 
intermediate product in the process of active DNA demethylation and to represent an epigenetic 
modification regulating chromatin or transcriptional factors (Kriaucionis and Heintz, 2009; 
Tahiliani et al., 2009). Total 5hmC levels increase during development of the human cerebellum 
and chromosomal regions positive for this mark are linked with neurodevelopmental genes (Wang 
et al., 2012). 
In the mammalian genome, DNA methylation is mediated by DNA methyltransferases 1, 
3a and 3b (DNMT1, 3a, 3b). However, only DNMT3a and DNMT3b are able to exert de novo 
methylation, while DNMT1 is responsible for the maintenance of DNA methylation after 
replication (Klose and Bird, 2006). DNMTs are essential for embryonic development, and their 
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loss interferes with tissue homeostasis (Bird, 2002). DNMT3a and DNMT3b are expressed in 
NSCs and have a crucial function in neurogenesis and neuronal function (Okano et al., 1999; Wu 
et al., 2010). 
 
2.2 Histone modifications 
 
DNA methylation and demethylation are critical regulatory mechanisms underlying CNS 
development. Nevertheless, the ability of various regulatory factors to access their target genes is 
also influenced by chromatin modifications occurring at the histones level. Histones are essential 
proteins enabling the packaging of DNA into chromatin. They are responsible for the first level of 
chromosome condensation, the nucleosome. This protein-DNA complex is comprised of an 
octamer of core histone proteins and a 147bp long DNA segment wrapped around the histones 
(Figure 1). Every nucleosome core is composed of two molecules of each histone 2A (H2A), 
histone 2B (H2B), histone 3 (H3) and histone 4 (H4), and is separated from the next by a ~80bp 
DNA sequence, known as linker DNA. It is in this region that histone 1 (H1) binds, enabling the 
stabilization of the structure. All histones are subjected to post-translational modifications such as 
acetylation, methylation, phosphorylation, ubiquitination or sumoylation that primarily occur at 
the N-terminal tail of the proteins (Figure 1). The tagging of histones with specific modifications 
shapes the condensation of chromatin in different manners, modulating the ability of DNA to 
associate with the transcriptional machinery and thereby regulating gene expression (Graff and 
Mansuy, 2008; Kouzarides, 2007; Tessarz and Kouzarides, 2014). Histone acetylation is catalyzed 
by histone acetyl transferases (HATs) and is, in principle, linked to transcriptional activation. On 
the other hand, histone deacetylation is catalyzed by histone deacetylases (HDACs) and is 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
14 
 
associated with transcriptional repression. Histone methylation is related to both transcriptional 
activation and repression, depending on the amino acid residue that is modified. For instance, 
lysine methylation of histone tails is associated with both activation and repression of gene 
expression; hence the effect of histone methylation on gene expression differs according to the 
position in the histone tail and the number of methylation in the lysine residues. For example, H3 
methylation at lysine 4 (K4me), K36, and K79 leads to transcriptional activation, whereas H3 
methylation at K9 and K27 is associated with transcriptional silencing. Several of these histone 
marks are essential during CNS development as they enable the sequential activation and 
deactivation of neurogenic and gliogenic gene promoters, resulting in the production of neuronal 
and glial cells at the appropriate developmental stages (Murao et al., 2016). 
 
2.3 Non-coding RNAs 
     
Non-coding RNA (ncRNA) molecules are transcribed from DNA, but are not translated 
into proteins. Among these, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) play a 
variety of roles in fine-tuning gene expression by transcriptional and post-transcriptional 
regulation. Many studies have shown that, in addition to histone modifications and DNA 
methylation, ncRNAs also participate in the mechanisms that ensure the sequential production of 
distinct neural cell types from NSCs during development and, generally, in multiple aspects of 
brain development and connectivity (Follert et al., 2014). MiRNAs represent one of the best 
characterized groups of ncRNAs. They are approximately 21-23 nucleotides long and are known 
for binding to the 3’ untranslated region (UTR) of their mRNA targets and either degrading them 
or inhibiting protein translation, thus contributing to post-transcriptional repression of gene 
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expression (Figure 1) (Mehler, 2008). Certain miRNAs have been described to be restricted in a 
particular organ suggesting a tissue-specific function. Likewise, several miRNAs are brain specific 
and play an important role in neurogenesis and in the development of glial cells (Fiore et al., 2011), 
with some being preferentially expressed in neurons or in astrocytes and others being equally 
distributed (Smirnova et al., 2005). These small ncRNAs seem to be regulated upon brain 
development. For example, a group of brain-expressed miRNAs was reported to be upregulated 
during neuronal differentiation, suggesting a potential contribution in controlling the timing of 
neuronal fate specification (Sempere et al., 2004). Another study documented a sequential increase 
of specific miRNA clusters at different developmental stages of the murine brain (Miska et al., 
2004). 
Taken together, it is evident that epigenetic modifiers, such as DNA methylation, histone 
modifications and RNA-mediated processes, accurately drive the development of the brain 
influencing lineage commitment of CNS cells, including neurons, oligodendrocytes and 
astrocytes.   
 
3. Differentiation of NSCs into astrocytes 
 
NSCs have the ability to self-renew and to differentiate into neurons, oligodendrocytes and 
astrocytes. Throughout mammalian brain development, the process of differentiation towards a 
neurogenic or gliogenic fate is finely timed and regulated.  During the fetal expansion phase, NSCs 
self-replicate via symmetric cell division, whilst later, during mid-gestation, they undergo 
asymmetric cell division and receive cues to differentiate into neurons. Lastly, in late-gestation to 
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perinatal periods they enter the gliogenic phase and differentiate into astrocytes and 
oligodendrocytes (Hirabayashi and Gotoh, 2005; Takouda et al., 2017).  
 
3.1 Key extracellular signals and transcriptional activators 
 
3.1.1 The Notch pathway 
 
The choice of NSCs between a neuronal and a glial cell fate is tightly regulated by 
environmental and intrinsic factors. Numerous studies have shown that specific signals, such as 
the neurogenic basic helix-loop-helix (bHLH) transcription factors, are involved in fate 
determination of the three neural lineages. They can, for example, promote the production of 
neurons whilst concurrently inhibiting the acquisition of glial fate. For instance, the pro-neural 
genes Achaete-Scute Family BHLH Transcription Factor 1 (ASCL1, MASH1), Neurogenin 1 
(NEUROG1), or Neurogenin 2 (NEUROG2) all promote  neuronal fate determination while 
suppressing expression of astrocytic genes (Nieto et al., 2001; Sun et al., 2001). Inhibition of 
neurogenesis induced by pro-neural genes requires expression of transcriptional repressors such 
as HES1 and HES5, which are the downstream targets and effectors of the Notch pathway. The 
Notch signaling is highly conserved (for review see:(Louvi and Artavanis-Tsakonas, 2006)) and 
comprises four transmembrane Notch receptors (Notch1-4) and several ligands (Jagged1-2 and 
Delta-like1-4). Binding of the ligands to Notch receptors induces a proteolytic cleavage of the 
receptor resulting in the release of the Notch intracellular domain (NICD). Once released, the 
NICD fragment is translocated to the nucleus where it acts as a transcriptional coactivator. NICD 
cannot bind directly to DNA, but instead interacts with the DNA binding protein, suppressor of 
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hairless (RBP-J) to initiate transcription of Notch target genes, such as the HES gene family 
(Andersson et al., 2011; Borggrefe and Oswald, 2009). Notch signaling is required to maintain a 
balance between the progenitor cell pool and its differentiating progeny (Borggrefe and Oswald, 
2009; Imayoshi et al., 2010). In addition, Notch signaling promotes a glial cell fate while neuronal 
identity is repressed (Gaiano et al., 2000; Louvi and Artavanis-Tsakonas, 2006; Taylor et al., 
2007). Later, Notch inhibits generation of both neurons and oligodendrocytes and promotes the 
differentiation of astrocytes (Grandbarbe et al., 2003). 
 
3.1.2 The JAK-STAT signaling pathway 
 
Following astrocyte specification, the first step of astrocytic differentiation is loss of 
neurogenic competence and expression of astrocytic genes. Members of the interleukin (IL)-6 
family of cytokines, including leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF) 
and cardiotrophin-1, bind to their cognate receptors inducing their dimerization. This enables the 
receptor-associated Janus kinase (JAK) to autophosphorylate and become activated. JAKs in turn 
phosphorylate and activate signal transducer and activator of transcription 3 (STAT3) enabling 
formation of homodimers. STAT3 homodimers subsequently translocate to the nucleus where they 
bind to the promoters of astrocytic genes, including GFAP, permitting its expression resulting in 
astrocytic differentiation (Bonni et al., 1997).  The JAK-STAT signaling pathway regulates several 
distinct cellular events including stem cell self-renewal and pluripotency capacity (Niwa et al., 
1998; Raz et al., 1999), proliferation in Drosophila germ (Tulina and Matunis, 2001) and intestinal 
lines (Beebe et al., 2010). In all these cases, STAT3 governs expression of genes that determine 
cell identity. It might be that this common pathway essential for astrocyte differentiation and stem 
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cell self-renewal reinforces the similarities between these cells and reflects a potentially 
evolutionary remnant of plasticity.  
 
3.1.1 The BMP pathway 
   
The bone morphogenetic protein (BMP) pathway also plays a role in astrocyte 
differentiation. BMP signaling activates the transcription factors SMAD1, 5 and 8 to form a 
complex which translocates to the nucleus to activate its target genes. BMPs have an important 
role in NSCs fate determination. Notably, SMADs inhibit oligodendrocyte development, but 
promote both neurogenesis and astrogliogenesis as well as astrocytic differentiation and 
maturation (Mabie et al., 1999; Setoguchi et al., 2004; Xiao et al., 2010). For example, BMP 
signaling promotes astrocytes maturation through phosphorylation of SMAD1/5/8 pathway 
leading to acquisition of a process-bearing morphology and expression of the most common 
astrocytic markers GFAP,  Aquaporin 4 (AQP4), and S100B (Scholze et al., 2014). Moreover, in 
vivo, in a BMP receptor double knockout mouse (Bmpr1a and Bmpr1b), the number of astrocytes 
was decreased between 25-40 % (See et al., 2007). Astrocyte number is also reduced in vitro, 
following inhibition of BMP by noggin, while the oligodendrocyte number is increased (Cate et 
al., 2010). Notably, both STAT3 and SMAD1 form a complex that is bridged by the coactivator 
p300 leading to induction of astrocytic genes in a synergistic manner (Nakashima et al., 1999). 
Both the levels and timing of expression of pro-astrogenic genes is critical for successful 
orchestration of initiation, maintenance and termination of differentiation. However, some of these 
components are also involved in the maintenance of stem cell identity, thus emphasizing their fine-
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
19 
 
tuned regulation of NSCs and astrocyte uniqueness. This duality must be accommodated in any 
forward translational strategy.  
The signaling pathways responsible for the astrocytic differentiation represent the essential 
players in physiological astrogenesis, but these mechanisms are not sufficient to define the 
spectrum of gene activity that occurs upon astrocytic differentiation.   
 
3.2 Importance of DNA methylation in the acquisition of the astrocytic fate 
 
In the CNS, cell intrinsic factors and extracellular cues influence the onset of 
astrogliogenesis. Concomitantly, dramatic changes in DNA methylation of astrocyte-specific 
promoters contribute to the neurogenic to gliogenic switch. This process explains why the 
responsiveness of NSCs to the astrogenic signaling pathways varies according to developmental 
stages. For example, early-derived cortical precursor cells are not able to undergo astrocytic 
differentiation in the presence of LIF, even though they express functional LIF receptors (Molne 
et al., 2000). In contrast, cultures of murine neuroepithelial cells derived from embryonic day (E) 
14 differentiate readily into astrocytes upon LIF stimulation. However, GFAP is not expressed in 
cultures from E11.5 neuroepithelial cells even when the STAT3 pathway is induced (Takizawa et 
al., 2001). These studies reveal that the well-coordinated switch from neurogenic to astrogenic fate 
is not solely dependent on the presence of extracellular factors, but also requires intrinsic 
determinants.  
During neuronal differentiation, astrocyte-specific gene promoters are methylated and 
transcription is silenced. However, in late-gestation many astrocytic genes become demethylated 
enabling NSCs to acquire gliogenic competences (Hatada et al., 2008). Recently, directly isolated 
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murine neural stem and progenitor cells from different developmental stages (E11.5, 14.5 and 
18.5) were used to determine the DNA methylome of each stage, revealing distinct and successive 
waves of global DNA methylation/demethylation that regulate the sequential generation of 
neurons, astrocytes and oligodendrocytes in the developing brain (Sanosaka et al., 2017). Notch 
ligands expressed in neuroblasts and immature neurons during mid-gestation activate their 
neighboring NSCs by inducing expression of the transcription factor nuclear factor I A (NFIA). 
NFIA in turn performs a dual act: it induces demethylation of the GFAP promoter and promotes 
dissociation of DNMT1 from the GFAP promoter, unveiling its STAT binding site (Namihira et 
al., 2009) (Figure 2). Deletion of the Dnmt1 gene results in demethylation of astrocytic genes and 
of genes involved in the JAK-STAT signaling pathway. Consequently, increased STAT activity 
and expression of astrocyte-related genes leads to precocious astroglial differentiation (Fan et al., 
2005). Further, specific deletion of Dnmt1 in NSCs increased the generation of astrocytes in the 
dentate gyrus (Noguchi et al., 2016b).  Ablation of Dnmt1 during late embryonic development did 
not impact astrogliogenesis per se, but Gfap expression was upregulated in the existing astrocytes 
of adult mice (Noguchi et al., 2016a). In addition, DNA methylation has an important role in the 
control of expression of the immature astrocytic marker S100B. Methyl CpG binding protein 2 
(MECP2), a protein linked to gene silencing which recruits histone deacetylases (HDACs) and 
corepressors, is bound on the promoter region of  S100b  inactivating gene expression. However, 
at E14 a specific cytosine residue of a CpG site within the promoter region is demethylated and 
MECP2 can no longer bind to this site leading to the initiation of murine S100b expression 
(Namihira et al., 2004) (Figure 2).  AC
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Overall, it appears that demethylation of astrocyte-specific gene promoters is crucial for 
the timely activation of gene expression and therefore for the regulation of astrocyte differentiation 
in the developing brain.  
 
3.3 Histone modifications associated to astrocytic differentiation  
 
During neural development, both neurogenic and gliogenic gene promoters undergo 
various histone modifications, which ensure the sequential production of each cell type. In the 
neural tube at E14, exposure of neuroepithelial cells to the astrocyte inducing cytokine BMP2 
resulted in a significant increase of histone H3 acetylation in the S100B gene promoter (Namihira 
et al., 2004). During astrocyte differentiation, LIF acts synergistically with retinoic acid (RA) to 
induce an open chromatin conformation through histone H3 acetylation, resulting in activation of 
the GFAP promoter in NSCs (Asano et al., 2009). RA receptors (RARs) form complexes with 
retinoid X receptors (RXRs) and bind to RA response elements in the promoter regions of target 
genes. When the RA ligand is absent, RAR/RXR associates with transcriptional repressors leading 
to gene silencing by recruitment of HDACs (Figure 2). Conversely, binding of RA enables the 
release of HDACs from the RAR/RXR complex and the recruitment of histone acetyltransferase 
(HAT) co-activators. Thus, RA-bound RAR/RXR associates with the GFAP promoter allowing 
the chromatin to adopt an open conformation through histone H3 acetylation, specifically in the 
STAT site-containing region. This facilitates efficient binding of STAT3 to the promoter, therefore 
inducing GFAP expression (Asano et al., 2009) (Figure 2). In addition, activated STAT3 is able 
to recruit the transcriptional co-activators CBP/p300, resulting in acetylation of H3K9 and H3K14 
at the GFAP promoter (Figure 2). These histone modifications further lead to enhanced H3K4me3 
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and recruitment of RNA polymerase II and activation of gene transcription (Cheng et al., 2011). 
Intriguingly, histone deacetylase 3 (HDAC3) was reported to regulate the switch between 
oligodendrocyte and astrocyte fate; deletion of HDAC3 induces robust astrocyte differentiation 
with concomitant loss of oligodendrocytes (Zhang et al., 2016). Similarly, inhibition of HDACs 
either with trichostatin A or sodium butyrate reduced GFAP expression in human astrocytes and 
reorganized the intermediate filament network of the cells (Kanski et al., 2014). Further histone 
modifications are for the expression of GFAP. Fibroblast growth factor 2 (FGF2), which regulates 
the competence of rodent cortical progenitors to differentiate into astrocytes in response to CNTF, 
facilitates access of the signal transducer and activator of transcription/CRE binding protein 
(STAT/CBP) to the GFAP promoter by strongly increasing H3K4me while blocking H3K9me 
around STAT binding site of the GFAP promoter (Figure 2). Since H3K4me and HeK9me are 
linked to transcriptional activation and repression respectively, FGF2 alters H3 methylation in a 
way that favors the activation of the Gfap promoter (Song and Ghosh, 2004).  
Deposition of repressive histone marks is also evident during astrocyte differentiation. 
ERG-associated protein with SET domain (ESET) protein, a H3K9 histone methyltransferase 
(HMT), is highly expressed during the early stages of brain development, but it is strongly 
downregulated during the transition from neurogenesis to astrogenesis. The GFAP promoter is a 
direct target of ESET and its expression at early stages is repressed via elevated H3K9me3 marks 
(Tan et al., 2012).  At later stages of brain development where ESET levels are reduced, H3K9me3 
is decreased and GFAP is activated (Figure 2). Similarly, the histone demethylase known as gene 
amplified in squamous cell carcinoma 1 (GASC1) is important for the developmental stage-
dependent differentiation of astrocytes. GASC1 hypomorphic mutant mice exhibit an increased 
amount of GFAP+ cells in the forebrain together with abnormal behaviors and synaptic activity 
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(Sudo et al., 2016). The roles of astrocytes on synaptic plasticity may partially explain why the 
mutant mice present such phenotypes and further help to understand the abnormal behaviors. 
Moreover, deletion of Enhancer of zeste homolog 2 gene (EZH2), encoding a polycomb group 
protein which is a H3K27 HMT, on cortical progenitor cells leads to accelerated astrocyte 
differentiation (Pereira et al., 2010).  
On the other hand, the H3K4, lysine-specific demethylase 5A (KDM5A) is pivotal for the 
repression of astrocyte differentiation in NSCs. Knockdown of KDM5A in NSCs increases the 
generation of astrocytes, while KDM5A overexpression reduces transcriptional activity of the 
GFAP promoter. Induction of astrocytic differentiation reduced recruitment of KDM5A to the 
GFAP promoter and increased H3K4me, thus maintaining NSCs in an undifferentiated state by 
suppression of astrogliogenesis (Kong et al., 2017). 
 
3.4 Essential miRNAs for the generation of astrocytes 
 
Several studies unveiled the important regulatory role that miRNAs play in astrocyte 
differentiation. During glial specification, miR-153 targets NFIA and NFIB mRNAs, an essential 
step for the initiation of astrocyte differentiation (Figure 2). Overexpression of miR-153 delayed 
the onset of astrogenesis favoring an undifferentiated state, while inhibition of miR-153 induced 
premature gliogenesis (Tsuyama et al., 2015). In early developmental stages of the forebrain, miR-
153 is highly expressed. As CNS development progresses, the levels of miR-153 are reduced 
followed by increased NFIA/B expression, revealing its role in astrocyte fate specification. 
MiR-31 was shown to be necessary for the specification and differentiation of astrocytes. 
In NSCs, miR-31 is suppressed by multiple stem cell factors, such as LIN28, C-Myc, SOX2 and 
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OCT4. However, upon astrogliogenesis, miR-31 is upregulated via the STAT3 and SMAD1/5/8 
signaling pathways contributing to the promotion of astrocyte differentiation, in part by targeting 
and reducing Lin28 mRNA levels. Indeed, in the absence of miR-31, astrocytes fail to properly 
differentiate, while overexpression of miR-31 is able to partially induce astrocyte differentiation 
(Meares et al., 2018).  
Investigations into the role of Chicken ovalbumin upstream promoter-transcription factors 
I and II (Coup-tfI and Coup-tfII) during CNS development have identified miR17/106 as another 
important regulator of the neurogenic to gliogenic switch. COUP-TFI/II is transiently expressed 
in the ventricular zone of early embryonic CNS. Double knockdown of Coup-tfI/II in NSCs 
resulted in greater silencing of the STAT3-binding site of the Gfap promoter due to reduction of    
acetylated histone H3 and dimethylated H3K4 (H3K4me2) and increase of H3K9me2. In the 
developing mouse forebrain, double knockdown of the transcription factors inhibited the initiation 
of astrogenesis (Naka et al., 2008). Later on, the same group identified miR17/106 as a 
downstream regulator of COUP-TFI/II. The mRNA of p38, which is pivotal for the physiological 
process of astrogenesis, was found to be a direct target of miR17/106 (Naka-Kaneda et al., 2014). 
Therefore, it seems that miR17/106 is an important regulator of the neurogenic to gliogenic switch. 
 
4. Spinal cord/traumatic brain injuries and neurodegenerative disorders 
 
Apart from their importance and multifunctionality in the healthy CNS, astrocytes respond 
to brain damage, infection or disease through a process known as reactive astrogliosis. The first 
description of astrocyte reactivity was documented by Virchow, showing that the spinal cord tissue 
was more fibrillary in neurosyphilis patients than in healthy individuals (Barcia et al., 2016). The 
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concept of astrocyte reactivity emerged with the discovery of the intermediate filament GFAP 
(Eng et al., 1971) and strong GFAP expression in astrocytes became a sign of reactivity (A. and 
DORIS, 1976). Another distinctive attribute of reactive astrocytes reported by early 
neuropathologists was hypertrophy as evidenced by enlarged cell body and processes 
(Wilhelmsson et al., 2006).  During astrogliosis, the glial scar formation is accompanied with the 
appearance of newly proliferated astrocytes. Human specimens showed evidence of astrocytic 
proliferation in response to a variety of insults, such as infection and acute demyelinating lesions 
(Colodner et al., 2005). However, if these newly divided astrocytes have been originated either 
from mature astrocytes that re-entered the cell cycle or from local progenitor cells is still a matter 
of investigation (Buffo et al., 2008; Carlen et al., 2009). 
Astrogliosis is primarily associated with neuroprotection. For example, during ischemia, 
reactive astrocytes (i) protect neurons from oxidative stress through a glutathione dependent 
mechanism (Chen et al., 2001; Iwata-Ichikawa et al., 1999), (ii) offer protection from NH4+ 
toxicity (Rao et al., 2005),  (iii) contribute to BBB repair (Tian et al., 2011), (iv) participate in the 
water brain homeostasis (Zador et al., 2009) and (v) are involved in the clearance of excitotoxic 
glutamate (Brown, 1999; Rothstein et al., 1996). The subsequent formation of the glial scar acts 
as a physical insulator to contain the lesioned area. Selective ablation of reactive astrocytes in adult 
mice expressing a herpes simplex virus-thymidine kinase from the Gfap promoter by treatment 
with ganciclovir, led to pronounced inflammatory responses, leukocyte infiltration, extensive 
tissue disruption, increased demyelination, neuronal degeneration, and failure of the BBB repair 
(Faulkner et al., 2004; Myer et al., 2006; Voskuhl et al., 2009). 
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4.1 The molecular repertoire of reactive astrocytes 
 
At the molecular and functional levels, astrogliosis is highly diverse (Anderson et al., 
2014); even in the same region of the mouse cerebral cortex, astrocytes respond heterogeneously 
to stab wound injury. In fact, although it was shown that almost all astrocytes become hypertrophic 
and overexpress GFAP following injury, some had their processes polarized towards the lesion, 
others proliferated and others remained static (Bardehle et al., 2013). In addition, activated 
astrocytes acquire NSC properties and modify not only their phenotypic profile, but they also 
undergo major gene expression changes. The transition from a normal to a reactive astrocytic 
phenotype is induced by extra- and intra-cellular signaling and epigenetic mechanisms that 
triggers, resolves or maintains astroglial reactivity. The machinery that will promote the 
“conversion” of astrocytes depends on the specific injury or degeneration event. Several epigenetic 
factors and signaling pathways have been described to play a role in astrogliosis, including the 
JAK/STAT pathway, the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
pathway, and the MAPK pathway (Ben Haim et al., 2015).   
 
4.1.1 Reactive astrocytes in spinal cord and traumatic brain injuries 
 
Following CNS injury, activated microglia react rapidly and recruit astrocytes by secreting 
several pro-inflammatory mediators including tumor necrosis factor-alpha (TNF), IL-1β, IL-6, and 
interferon-gamma (IFN-γ) (Sofroniew and Vinters, 2010). Reactive astrocytes can proliferate, 
become hypertrophic and migrate to the site of the injury leading to the formation of a physical 
glial barrier that impedes axonal regeneration in chronic spinal cord injury (SCI). Nevertheless, 
ablation of reactive astrocytes or interference with their activation mechanism upon injury, results 
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in exacerbated tissue degeneration and spread of inflammatory cells indicating that the glial scar 
has a potential function (Karimi-Abdolrezaee and Billakanti, 2012). The transcription factor NF-
κB is responsible for triggering gene expression of several inflammatory mediators during 
inflammation (Figure 3). Astrocyte-specific inactivation of NF-κB resulted in improved functional 
recovery following SCI (Brambilla et al., 2005). Notably, NF-κB activation of astrocytic cultures 
by TNF was unable to induce a reactive phenotype, but seemed to convert astrocytes into neural 
progenitor-like cells (Gabel et al., 2016). After SCI, JAK-STAT signaling is also activated (Figure 
3). Reactive astrocytes in STAT3 conditional knockout mice showed limited migration to the 
lesion site, failure of astrocyte hypertrophy and GFAP upregulation, widespread leukocyte 
infiltration, neural disruption and demyelination (Herrmann et al., 2008; Okada et al., 2006). 
Furthermore, the investigation of astrocyte-related signaling responses resulting from diverse 
neurotoxic insults, revealed the implication of STAT3 pathway as a broadly triggered signaling 
pathway for astrogliosis (O'Callaghan et al., 2014).  
It is evident that in response to different injury or inflammatory stimuli, distinct pathways 
are stimulated, all leading to astrocytic activation. Fibrinogen, a blood protein that leaks into the 
CNS following BBB disruption, was discovered to activate transforming growth factor-beta (TGF-
β) signaling pathway after traumatic CNS injury. Activation of TGF-β results in neurite outgrowth 
inhibition, while inhibition of TGF-β signaling attenuated glial scar formation (Schachtrup et al., 
2010). Toxin-induced reactive gliosis in the corpus callosum showed that endothelin-1 induces 
astrocyte proliferation and GFAP expression through activation of ERK- and c-Jun N-terminal 
kinase (JNK)-dependent pathways (Gadea et al., 2008) (Figure 3). Similarly, traumatic scratch 
injury in astrocytes triggered a calcium influx from the extracellular compartment and activated 
the JNK pathway to activate GFAP expression (Gao et al., 2013). 
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Transcriptomic analysis of reactive astrogliosis showed that gliosis consists of a rapid 
induction of gene expression after insult and identified lipocalin 2 (LCN2) and Serpina3 as robust 
markers of reactive astrocytes (Zamanian et al., 2012). Initially described as iron-trafficking 
protein involved in multiple processes such as apoptosis, innate immunity and renal development, 
LCN2 is secreted in several brain injury conditions such as inflammation (Jin et al., 2014) and 
stroke (Elneihoum et al., 1996), or in response to neurodegeneration (Bi et al., 2013). It also 
promotes apoptosis, morphological changes, and migration of astrocytes both in vitro and in vivo. 
In all cases, it has been detected in high amounts predominantly in astrocytes and to be selectively 
toxic to neurons. In fact, LCN2 deficiency reduced astroglial-induced neurotoxicity in vitro (Jin et 
al., 2014) and resulted in a significant attenuation of hippocampal neuronal loss, white matter 
damage, BBB permeability and cognitive decline in a mouse model of cerebral ischemia (Kim et 
al., 2017). NF-κB and STAT3 are able to regulate the expression of LCN2 (Figure 3). Intriguingly, 
LCN2 is capable of initiating the activation of JAK2/STAT3 and NF-κB signaling pathways to 
induce the production of chemokines and astrocytic cell migration (Lee et al., 2011) (Figure 3), 
thus establishing a positive feedback loop which maintains astrocytes in a reactive state. 
Interestingly, a recent study using a SCI mouse model defined three distinct astrocytic 
populations based on their marker genes: naive, reactive and scar-forming astrocytes (Hara et al., 
2017). When reactive astrocytes were transplanted into naive or injured spinal cord models, they 
were converted to naive astrocytes or formed astrocytic scars respectively, unveiling their 
environment-dependent plasticity. Upregulation of genes associated with type I collagen in the 
lesioned area following SCI is responsible for the conversion of reactive into scar-forming 
astrocytes. Pharmacological blockage of reactive astrocyte–type I collagen interaction was 
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sufficient to prevent scar formation strengthening the beneficial effect of reactive, but not scar-
forming astrocytes (Hara et al., 2017). 
Traumatic brain injury (TBI) is an acute injury of the brain resulting in a direct neuronal 
loss followed by a neuroinflammatory phase. In the acute stage, the neuroinflammatory “cascade” 
attempts to respond against brain damage. However, in the chronic stage, this reaction leads to 
neurodegenerative-like symptoms, including diminished or altered state of consciousness, 
impaired motor and cognitive skills (Lozano et al., 2015). In an effort to treat TBI, the 
hematopoietic growth factor granulocyte colony-stimulating factor was used in a TBI mouse 
model resulting in behavioral recovery associated with increased astrogliosis and hippocampal 
neurogenesis. Activated astrocytes participated together with microglia in the release of 
neurotrophic factors to mediate repair and enhance survival of injured neurons (Song et al., 2016). 
In a TBI rat model, the increase of GFAP+ cells under brain injury revealed the possible 
involvement of astrocytes in perivascular caspase‐3‐mediated apoptosis (Glushakova et al., 2018). 
 
4.1.2 Reactive astrocytes in neurodegenerative diseases  
 
Given the multitude of vital roles that astrocytes play in the regulation of brain physiology, 
it is not surprising that reactive astrocytes are involved in the initiation and progression of age-
related neurodegenerative diseases including AD, PD, and amyotrophic lateral sclerosis. 
The most prevalent neurodegenerative disease is AD, which is accompanied by a 
progressive accumulation of senile plaques, mainly composed of amyloid β (Aβ), and 
neurofibrillary tangles composed of tau protein. Tissue samples from AD patients present an 
overabundance of reactive astrocytes that are closely associated with amyloid plaques in the 
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cerebral cortex. A remarkable and stereotypical spatial organization of glial cells around Aβ 
plaques has been recently characterized, with an inner shell of amoeboid/activated microglia and 
an outer shell of reactive and polarized astrocytes, a structure described as “reactive glial net” 
(Bouvier et al., 2016). Reactive astrocytes endocytose Aβ peptides released from degenerating 
neurons, resulting in the toxic accumulation of Aβ, followed by astrocytic death and subsequent 
release of Aβ (John Lin and Deneen, 2013; Maragakis and Rothstein, 2006).  
Extracellular cues play important regulatory roles of the expression of astrocyte-specific 
genes during astroglial development and it is possible that similar mechanisms are responsible for 
controlling gene expression in neurodegenerative diseases. Activation of JAK2/STAT3 pathway 
precedes the onset of astrogliosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
mouse model of PD (Sriram et al., 2004). On the other hand, deletion of astrocytic STAT3 in the 
MPTP model markedly reduced the number of reactive astrocytes (O'Callaghan et al., 2014). 
These observations clearly identify a role for activated STAT3 in astrocyte damage, induction of 
astrogliosis and possibly GFAP upregulation. In the MPTP mouse model, increased expression of 
wingless-type MMTV integration site1 (WNT1) was attributed to reactive astrocytes. It was shown 
that Wnt1, together with other factors derived by these cells, promoted the generation of 
dopaminergic neurons from adult NSCs in vitro, and that pharmacological activation of Wnt/β-
catenin pathway in vivo enabled the recovery of dopaminergic neurons, revealing a neuroprotective 
effect of Wnt signaling and reactive astrocytes in PD (L'Episcopo et al., 2011). Wnt signaling 
regulates the development of midbrain dopaminergic neurons and is required for their 
differentiation (Arenas, 2014). In addition, Wnt proteins are abundantly present in the adult brain 
maintaining and protecting neuronal functions, including the dopaminergic neurons of the 
substantia nigra (Inestrosa and Arenas, 2010). On the other hand, canonical Wnt signaling is 
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upregulated in PD and proteins encoded by PARK genes, involved in familial PD, have been shown 
to modify Wnt signaling by regulating β-catenin levels or by interacting with key Wnt signaling 
components (Berwick and Harvey, 2014). Further exploration of the role of the Wnt pathway in 
astrocytic function and their subsequent beneficial effect on dopaminergic neurons might be of 
significant importance in order to fully understand the contribution of reactive astrocytes to both 
neurodegeneration and neuroprotection during ageing. 
 
4.1.3 Heterogeneity of reactive astrocytes 
 
As it was discussed, in response to threatening events, astrocytes could adopt protective or 
deleterious relationships towards neural tissue. In fact, gene expression analysis of reactive 
astrocytes derived from stroke or inflammatory mouse models revealed the existence of two 
distinct context-dependent populations with distinct phenotypes that relied on the type of the injury 
(Zamanian et al., 2012). While reactive astrocytes from the different models shared several 
deregulated genes, at least 50% of the altered genes were unique for each condition. Reactive 
astrocytes in ischemia (called A2 astrocytes) seem to possess a molecular identity that may be 
protective, while the ones activated by LPS (namely A1 astrocytes) have a negative effect. This 
type of astrocyte was found abundantly in several neurodegenerative diseases, including PD, AD 
and Huntington’s disease (Liddelow et al., 2017). Recently, it was shown that aged astrocytes 
acquired an A1-like identity that depends on the brain region. It was suggested that this type of 
astrocyte might contribute to cognitive decline in normal aging, while increasing the vulnerability 
of the aged brain during injury (Clarke et al., 2018). These studies highlight the heterogeneity of 
astrogliosis, where astrocyte activity depends on the type of inducing injury and constitute an 
additional hint that epigenetic mechanisms may participate in this astrocytic response since 
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different genes must be activated each time in response to specific stimulations. Accurate 
coordination of gene expression depending on the type of injury is necessary and it appears that 
this expression is additionally brain region- and age-specific. It is possible that the same molecular 
pathways are used in CNS insults, leading to different expression patterns at each time. In this 
sense, this diverse responsive ability of astrocytes unveils their highly plastic potential and offers 
an opportunity for this to be exploited in therapeutic strategies. 
 
4.2 MiRNAs’ functioning in the process of astrocyte reactivity 
 
Similarly to astrocyte differentiation, epigenetic regulation plays a role in reactive 
astrogliosis as well. For example, multiple miRNAs have been reported to be modulated upon 
reactive astrogliosis. MiR-145, enriched in rat spinal neurons and astrocytes, was found to be a 
negative regulator of astrogliosis. It was downregulated in SCI and astrocyte-specific 
overexpression of miR-145 decreased the size of astrocytes and their proliferative and migratory 
abilities. GFAP and MYC mRNAs were suggested as potential targets of miR-145 (Wang et al., 
2015) (Figure 3). MiR-145 has also been detected at low levels in human embryonic stem cells 
(hESCs) and increasing levels during differentiation suppress the pluripotency genes OCT4, SOX2 
and KLF-4 (Figure 3) (Xu et al., 2009). An important aspect would be to identify whether miR-
145 reduction in SCI is able to activate the neural stem cell genes in astrocytes, enabling them to 
obtain an immature identity and if miR-145 downregulation contributes to the acquisition of a stem 
cell-like fate in an attempt to restore the brain damage and regenerate. 
In contrast to the down-regulation of miR-145, miR-21 was upregulated in a time-
dependent manner after SCI in mouse. Inhibition of miR-21 abrogated the increased expression of 
reactive markers such as GFAP (Figure 3), augmented astrocytes’ hypertrophic response and 
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increased axon density in the site of the lesion (Bhalala et al., 2012), depicting the detrimental 
effects of increased miR-21 levels upon injury. This study revealed a novel role of miR-21 in 
regulation of astrocyte hypertrophy and glial scar progression. Interestingly, BMP signaling has 
been described to modulate miR-21 levels in cultured astrocytes (Sahni et al., 2010), and a miR-
21 regulatory sequence contains two STAT3-binding sites, providing the possibility that astrocytic 
miR-21 levels may also be regulated by JAK-STAT signaling (Loffler et al., 2007).   
MiR-140 was shown to suppress normal astrocytic cell proliferation by binding to the 3’ 
UTR of brain-derived neurotrophic factor (BDNF) mRNA inhibiting its translation (Figure 3). 
LPS-induced inflammation resulted in increased production of BDNF, IL-6 and TNF, which were 
restored with ectopic miR-140 expression (Tu et al., 2017). Glioma patients also present low 
amount of miR-140, which has been shown to restrict tumor growth and metastasis. The anti-
proliferative effect of miR-140 may be used to restrict the detrimental effects of reactive 
astrogliosis on the damaged tissue and as a potential therapeutic strategy for cancer patients.  
The family of miR-181 was reported to be present in the mature CNS but not early in brain 
development, showing a high expression in astrocytes compared to neurons (Hutchison et al., 
2013). Induction of inflammation by treating mice with LPS leads to significant decrease of all 
miR-181 family members (Figure 3). Overexpression of miR-181c in astrocytic cultures exposed 
to LPS increased cell death and changes in the levels of miR-181 resulting in modified expression 
of several inflammatory cytokines. Interestingly, mRNAs encoding MeCP2 and X-linked inhibitor 
of apoptosis were identified as miR-181 targets. Notably, in the hematopoietic system, miR-181 
represses LIN28, a well-described pluripotent marker, mediating stem cell differentiation (Li et 
al., 2012). Further investigation of the possible role of miR-181 towards cell fate specification 
during brain development would be of great value. These findings unveil the important role of 
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miRNAs in the molecular responses of astrocytes under inflammatory conditions and illustrate 
how they alter the astrocytic transcriptome under reactive astrogliosis. 
Although it has been recently shown that a TNF treatment of murine astrocytes 
differentiated from neural precursor cells in vitro resulted in the modifications in the levels of 
H3K4me3 and H3K27me3 at the promoters of specific genes (Michelucci et al., 2016), evidences 
on the extents of DNA methylation and histone modifications in reactive astrocytes are still 
lacking. Identifying additional epigenetic modifications that influence the process of astrocytic 
activation will be crucial not only to further understand the underlying mechanisms, but also to 
intervene and potentially attain functional recovery after a CNS injury or disease. However, it has 
to be borne in mind that reactive astrogliosis per se offers several protective roles to the CNS, such 
as uptake of potentially excitotoxic glutamate, repair of the BBB and limitation in the spreading 
of inflammatory cells or infectious elements from the injured or diseased tissue to the healthy parts. 
Interestingly, it is possible that some clinically approved drugs may act predominantly on 
astrocytes or on the astrocytic network, although originally designed for other targets (Pekny and 
Pekna, 2014). In this sense, it is possible that already available drugs are able to act on molecules 
selective to astrocytes or on epigenetic mechanisms related to reactive astrogliosis offering at least 
the possibility of adjusting the damage-recovery equilibrium within the CNS. 
Overall, the ability of astrocytes to become reactive, undergoing dramatic morphological 
and molecular changes, highlights their plasticity. Under specific environmental and intrinsic cues, 
this plasticity may also confer astrocytes the capacity to dedifferentiate, thus re-expressing features 
of NSCs, or even to be reprogrammed into a different cell lineage. 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
35 
 
5. Astrocyte plasticity: dedifferentiation and reprogramming 
 
Cellular plasticity refers to the ability of cells to change their fate identity in response to 
microenvironmental stimuli. Astrocytes exhibit a high degree of morphological and functional 
plasticity. Recent reports have shown that astrocytes can be converted into functional neurons both 
in vitro (Berninger et al., 2007; Heinrich et al., 2010) and in vivo (Liu et al., 2015; Torper et al., 
2013). In a mouse model of AD, reactive astrocytes were directly reprogrammed into functional 
neurons in response to NeuroD1 (Guo et al., 2014). Under physiological conditions, astrocytes 
generally remain in a quiescent state, but retain their capacity to resume proliferation. Fate 
mapping of astrocytes in the adult mouse cerebral cortex revealed that, after injury, a subset of 
mature astrocytes acquired stem cell properties and recapitulated features of early developmental 
stages (Buffo et al., 2008). This process was originally coined by the authors as 
“dedifferentiation”. Intriguingly, these cells were able to form neurospheres, to self-renew and to 
differentiate into neurons and oligodendrocytes in vitro. This was later confirmed in models of 
traumatic or ischemic brain injury (Shimada et al., 2012; Sirko et al., 2013). Furthermore, in vivo 
imaging of astrocytes following acute injury identified a subpopulation of proliferating reactive 
astrocytes enriched along blood vessels (Bardehle et al., 2013). Notch signaling is crucial for 
controlling neurosphere formation in the cultures of reactive astrocytes (Shimada et al., 2012). 
Finding routes to bypass the anti-neurogenic environment in the adult brain, due for example to 
BMP and Notch signaling, would potentially allow exploitation of the latent multipotency of 
reactive astrocytes to elicit neuronal repair. 
  
5.1 Influence of external stimuli 
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Different factors have been identified to induce the conversion of mature astrocytes into 
neural progenitors. In vitro, transforming growth factor alpha promotes sequential conversion of 
mature astrocytes into neural progenitors and stem cells (Sharif et al., 2007). This study described 
a novel population of mature astrocytes capable, in response to a single growth factor, to regress 
progressively into a neural stem-like cell stage via an intermediate glial progenitor stage. In vivo, 
Sonic hedgehog (SHH) signaling is a key mediator enabling astrocytes to retain latent stem cell-
like properties. Inducible deletion of SHH’s transducer Smoothened followed by stab injury in 
adult mice resulted in a significant reduction of proliferation in reactive astrocytes and to a 
decreased ability of these cells to form neurospheres in vitro (Sirko et al., 2013). Another study 
identified elevated SHH levels in astrocytes upon mechanical injury. In vitro incubation of 
astrocytes with conditioned medium derived from injured astrocytes enabled cells to acquire neural 
progenitor cell characteristics, including self-renewal, multipotency, downregulation of GFAP and 
S100B and upregulation of NES, SOX2 and CD133 (Yang et al., 2012). Notably, in the mouse 
forebrain, SHH acts as a mitogen in neural progenitor cells of the SVZ enabling them to proliferate 
and produce new interneurons in the olfactory bulb (Palma et al., 2005). Therefore, SHH is a 
crucial pathway during neurogenesis and astrocytes dedifferentiation, thus mirroring another 
important pathway shared by both NSCs and astrocytes.  
Further, the role of inflammatory mediators to induce astrocytes dedifferentiation has also 
been a matter of recent investigation. Exposure to the pro-inflammatory factor TNF of primary 
astrocytes prepared from newborn mice induces expression of several genes associated with the 
NF-κB pathway (Birck et al., 2016). More precisely, administration of TNF initiated loss of Gfap 
expression and the decrease of expression of genes related to glycogen metabolism. Moreover, a 
subset of these cells gained expression of stemness markers, including Oct4, CD44 and Musashi-
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1 as well as were able to form neurospheres giving rise to neural progenitors and neurons (Gabel 
et al., 2016). Notably, in vitro treatment with TNF or the BMP inhibitor noggin of murine 
astrocytes differentiated from neural precursor cells resulted in the acquisition of NSC-like 
properties accompanied by alterations in both the epigenome and transcriptome. Dedifferentiation 
of astrocytes was associated with modifications in the levels of H3K4me3 and H3K27me3 at the 
promoters of genes related to cell cycle, stemness or neuronal fate thereby permitting the re-
activation of neural progenitor markers (Michelucci et al., 2016).  
 
5.2 Effects of genetic manipulation  
 
As mentioned above, EZH2 is a HMT involved in NSC renewal and maintenance by 
inducing gene silencing via histone methylation and deacetylation. Forced expression of Ezh2 in 
postnatal mouse astrocytes resulted in partial, but not complete dedifferentiation of these cells 
accompanied with the downregulation of Gfap and S100B and the upregulation of NSC markers, 
including Nes and Sox2 (Sher et al., 2011), revealing the role of Ezh2 in retaining cells in the NSC 
state and even reverting differentiated cells into a more immature state. 
Additional studies suggested that reactive astrocytes share common characteristics with 
NSCs. Dicer is an indispensable enzyme of the miRNA machinery, responsible for the maturation 
of miRNAs. Selective deletion of Dicer in astrocytes resulted in transgenic mice that exhibited 
ataxia, profound neuronal degeneration of the cerebellum, seizures, and premature death. Prior to 
the onset of any neurological symptom, the transcriptome of Dicer-deficient astrocytes was 
modified in a way that resembled an immature molecular signature. Specifically, hallmark genes 
of immature/reactive astrocytes were upregulated, while astroglial genes related to mature 
functions were downregulated contributing to excitotoxicity and a failure to support normal mature 
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brain circuits (Howng et al., 2015; Tao et al., 2011). Collectively, Dicer and subsequently miRNA 
production are critically involved in the maintenance of astrocyte identity and function.  
These studies reveal that, besides the two neurogenic niches of the adult brain, 
subpopulations of mature astrocytes in other brain regions maintain their ability to dedifferentiate 
and acquire NSC-like properties under specific conditions. Nevertheless,  the origin of these plastic 
cells is still a matter of controversy, at least under stroke conditions where it was described that 
NSCs from the SVZ give rise to a subpopulation of reactive astrocytes in the cortex which 
contributes to astrogliosis and scar formation (Faiz et al., 2015). This is especially important in 
cell replacement therapies in order to obtain a desired cell fate and potentially regenerate damaged 
tissue. Forced expression of the transcription factor ASCL1 in astrocytes elicits GABAergic 
neurons, while expression of NEUROG2 induces glutamatergic neurons, and concomitant 
expression of CEND1 and NEUROG2 induces generation of a mixed GABAergic and 
dopaminergic neuronal population in vitro (Aravantinou-Fatorou et al., 2015; Berninger et al., 
2007; Heinrich et al., 2010). In 2013, several research groups managed to reprogram astrocytes 
into functional neurons in vivo. Overexpression of the single transcription factor SOX2 (Niu et al., 
2013) or NeuroD1 (Guo et al., 2014) or a combination of ASCL1, BRN2A, and MYT1Ll (Torper et 
al., 2013), was sufficient to directly reprogram astrocytes into neurons. Furthermore, it was shown 
that striatal astrocytes of stroke-induced mice entered a neurogenic program and generated new 
neurons (Magnusson et al., 2014). In a mouse model of Huntington’s disease, some activated 
striatal astrocytes acted as neural progenitors and gave rise to neurons in vivo (Nato et al., 2015). 
Activated astrocytes directly generated dopaminergic neurons in a Parkinson’s disease mouse 
model (Rivetti di Val Cervo et al., 2017). In vivo reprogramming of adult astroglial cells has 
emerged as a potential therapeutic approach that would avoid cell transplantation and possibly 
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immunosuppression. However, reprogramming is a time consuming process characterized by low 
efficiency. According to a population shift view of cellular reprogramming, a small population of 
cells already resides in energetically favorable trajectories that will allow them to respond more 
readily to reprogramming signals. Consequently, if expression of reprogramming signal is retained 
over time, stochastic fluctuations in the transcriptome and epigenome will permit other cells to 
enter this primed state, thereby progressively increasing the efficiency of reprogramming (Del Sol 
and Buckley, 2014). Unlocking the molecular mechanisms that control cell fate switch may lead 
to improvements in reprogramming efficiency and provide a regenerative medicine strategy for 
mitigating neuronal loss in degeneration or trauma. 
Taken together, the capacity of astrocytes to become reactive or be reprogrammed provides 
promise for endogenous brain repair strategies. However, these approaches have to be taken with 
caution as this may have unwanted side effects, such as tumorigenesis.  
 
6. Brain tumors of astrocytic lineage 
 
Gliomas represent the most common primary tumors of the CNS with an incidence rate of 
6.6 per 100.000 individuals in the USA (Ostrom et al., 2016). Adult diffuse gliomas are classified 
based on histopathological and molecular features in oligodendroglioma, astrocytoma, and 
Glioblastoma (GBM) (Louis et al., 2016). A fundamental feature of glioma is their cellular 
diversity, often reflecting pathological analogues of the normal tissue. In this cellular 
heterogeneity, the question of the cellular origin of gliomas remains largely unresolved. Current 
evidence indicates that NSCs (Lathia et al., 2015) as well as differentiated cells, such as astrocytes 
and even neurons, can give rise to gliomas (Friedmann-Morvinski et al., 2012). For the latter, it 
has been demonstrated that differentiated astrocytes transduced with oncogenic lentiviral vectors 
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are able to give rise to malignant gliomas that match a GBM subtype. Under these conditions, 
astrocytes enter a reprogramming mode, dedifferentiate and generate tumors that present a 
progressive loss of GFAP expression and are positive for several progenitor/stem cell markers 
including nestin and SOX2 (Friedmann-Morvinski et al., 2012). This is reminiscent of the high 
plasticity of reactive astrocytes under CNS insults. Likewise, following particular cues from the 
local microenvironment or genetic alteration, mature astrocytes dedifferentiate and obtain 
characteristics of neural precursor cells which can maintain their pluripotency and initiate 
tumorigenesis. A second study reported that the transduction of primary human astrocytes with 
lentiviral vectors expressing four defined genetic factors (Myc, Oct-4, p53DD and Ras) induced 
efficient generation of malignant cells with powerful tumor-initiating capabilities (Li et al., 2016). 
Indeed, when transplanted into immunodeficient mice, these transduced cells were sufficient to 
induce tumor formation, showed unlimited self-renewal and expressed typical glioma stem-like 
cell markers. In vitro cultivation of the transformed astrocytes revealed their potential to form 
spheres and differentiate into neuron-, astrocyte- and oligodendrocyte-like cells. The observation 
that reactive astrocytes are able to share common progenitor markers might explain why, under 
specific conditions, astrocytes may encompass the starting point of brain tumor formation, further 
supporting the concept that a fine line separate the dedifferentiated astrocytic fate towards 
reprogramming or tumorigenesis. 
In line with the loss of GFAP expression by dedifferentiated astrocytes, GFAP expression 
is usually silenced in a progressive manner with increasing grade of astrocytoma (Restrepo et al., 
2011). The fact that no GFAP mutations or major DNA rearrangements or deletions are detected 
in human glioma, prompted investigation of the role of epigenetic mechanisms in the loss of GFAP 
expression. Aberrant DNA methylation was detected in the promoter region of GFAP leading to 
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its downregulation (Restrepo et al., 2011). In contrast to GFAP silencing, DNMT1 and DNMT3B 
were found to be overexpressed in GBM. Specifically, the DNMT1 promoter was enriched with 
active chromatin marks, including acetylated histones H3, H4 and H3K4me2, in GBM patients 
and cell lines. Conversely, normal brain tissue exhibited enrichment of the repressive histone 
modifications H3K9me2 and H3K27me3. Furthermore, the DNMT3B promoter was 
hypomethylated in the same tissue and overexpression of these DNMTs led to inactivation of the 
tumor suppressor genes p21 and PTEN (Rajendran et al., 2011). Promoters of additional tumor 
suppressor genes including p16/CDKN2A (Costello et al., 1996), RB1 (Nakamura et al., 2001), 
p14(ARF) (Yin et al., 2002), PTEN (Baeza et al., 2003), MGMT (Blanc et al., 2004), RASSF1A 
(Gao et al., 2004), p73 (Yu et al., 2004) were all shown to be hypermethylated and silenced in 
gliomas, thus resulting in the deregulation of multiple signaling pathways responsible for cell 
growth and apoptosis. 
  
6.1 The importance of IDH genes 
 
Integrated genomic analysis of human GBM samples revealed recurrent mutations in the 
active site of isocitrate dehydrogenase 1 gene (IDH1) in a small number of GBM patients (Parsons 
et al., 2008), that later turned out to largely represent secondary GBM. Mutations in IDH2 gene 
have also been identified in gliomas (Yan et al., 2009). Under normal conditions, these enzymes 
catalyze the oxidative carboxylation of isocitrate to α-ketoglutarate, resulting in the production of 
NADPH. Glioma bearing mutated IDH1 or IDH2 display a glioma-CpG island methylator 
phenotype (G-CIMP) and produce high levels of D-2-hydroxyglutarate, proposed to inhibit several 
histone and DNA (de)methylases, including the TET enzymes (Chowdhury et al., 2011; Xu et al., 
2011). Almost all mutations in IDH1 in glioma occur at the amino acid residue 132 or the 
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analogous residue 172 in IDH2, with the vast majority presenting a substitution of arginine with 
histidine (R132H) (Balss et al., 2008). Introduction of this single point mutation in immortalized 
human astrocytes was sufficient for the alteration of specific histone marks and for inducing DNA 
hypermethylation, influencing the expression of approximately 600 genes (Turcan et al., 2012), 
although hypermethylation alone was not sufficient to induce tumorigenesis. Recently, the same 
research group identified enrichment of the active histone mark H3K4me3, the repressive histone 
marks H3K9me3, H4K20me3 and H3K36me3, which prevent intragenic cryptic transcript 
initiation in these cells. One gene that showed increased H3K4me3 was PDGFRA, already linked 
to gliomagenesis (Turcan et al., 2018). Taken together, these results show that IDH1 R132H 
mutation is able to reshape the chromatin state and transcriptome, however how this contributes to 
gliomagenesis remains to be determined. 
 
6.2 The methylation phenotype of brain tumors 
 
As indicated above, the IDH mutation is associated with a collective hypermethylation at 
a large number of loci signifying a G-CIMP (Noushmehr et al., 2010).  
Another critical epigenetic mark in glioma is the DNA repair enzyme O6-methylguanine-
DNA methyltransferase (MGMT), which repairs the naturally occurring mutagenic O6-
methylguanine to guanine, thereby protecting against mutagenesis and malignant transformation. 
The MGMT promoter is frequently methylated in GBM patients, leading to gene silencing, which 
has been related with increased sensitivity to alkylating agents used for cancer therapy in patients 
with GBM (Weller et al., 2010). A meta-analysis study conducted in GBM patients showed that 
MGMT promoter methylation was associated with better progression-free survival and overall 
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survival in these patients regardless of the fact of having received any therapeutic treatment and 
linked to longer overall survival in GBM patients treated with alkylating agents (Zhang et al., 
2013). Therefore, the prognostic and predictive value of MGMT promoter methylation in GBM 
patients is highly relevant.  
Analysis of diffuse glioma samples using different omics technologies including DNA 
methylation profiling, identified six distinct methylation clusters allowing the most robust and 
relevant distinction (Ceccarelli et al., 2016). A recent study suggests a new DNA methylation-
based classification of CNS tumors, offering a novel approach to tumor classification and 
diagnosis precision, further strengthening the importance of comprehending and assessing the 
cancer methylome and thus the epigenetic mechanisms that contribute to tumorigenesis (Capper 
et al., 2018). Generally, global DNA hypomethylation is common in cancer, including gliomas, 
and it is estimated to influence 10 million CpG dinucleotides per haploid tumor genome (Cadieux 
et al., 2006). Demethylation was described to mainly occur in satellite sequences and 
pericentromeric regions promoting genomic instability and reactivation of transposable elements, 
thereby leading to tumorigenesis through activation of oncogenes (Cadieux et al., 2006). 
  
6.3 Histone changes linked to Glioblastoma 
 
 Pediatric GBM as well as a subtype of adult GBM are characterized by the presence of 
somatic histone mutations. Two single point mutations have been described in the genes encoding 
the H3.3 (H3F3A) and H3.1 (HIST1H3B, HIST1H3C) histone variants. These mutations result in 
the substitution of lysine-to-methionine at position 27 (K27M) and glycine-to-arginine or -valine 
at position 34 (G34R/V) (Jones et al., 2017; Williams et al., 2017). It was reported that aberrant 
binding of mutant K27M to EZH2 inhibits the enzymatic activity of Polycomb repressive complex 
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2 which is needed to maintain gene repression. In addition, K27M mutation leads to a global 
reduction of H3K27me3 levels and to global DNA hypomethylation, events that drive gene 
expression, including those involved in neuronal differentiation and gliomagenesis (Bender et al., 
2013; Lewis et al., 2013; Venneti et al., 2013). However, a substantial gain of H3K27me3 and 
EZH2 at specific gene loci has also been reported, which can be advantageous for tumor cells if 
the silenced gene is a tumor suppressor as has been described for p16/CDKN2A (Chan et al., 2013).   
Comparative analysis of the chromatin state in GBM stem-like cells (GSCs) versus more 
differentiated tumor cells and nonmalignant neural cells revealed a prevalence of gene activation. 
Repressed promoters in human astrocytes lose the H3K27me3 mark in GSCs and become 
activated.  Among the upregulated genes, a large set of developmental transcription factors (TFs) 
was activated in GSCs. In particular, ASCL1, a member of the bHLH family and known to play a 
role in neuronal commitment and differentiation, was found to directly activate Wnt signaling and 
to be necessary for GSCs maintenance and their tumorigenicity in vivo (Rheinbay et al., 2013). 
The Wnt pathway has long been associated with oncogenesis (Polakis, 2007) and is also essential 
for maintaining NSCs in a self-renewing state (Kalani et al., 2008). Notably, ASCL1 is important 
for Müller glia activation, cells essential for retina regeneration in fish. LIN28, a downstream 
ASCL1 effector, decreases let-7 miRNA levels enabling expression of the pluripotency genes, 
KLF-4, OCT4 and MYC (Alunni and Bally-Cuif, 2016). The same LIN28/let-7 regulatory loop 
seems to be active in cancer stem cells, regulating their properties and contributing to oncogenesis 
(Chien et al., 2015; Sun et al., 2016), revealing how some molecular mechanisms are shared during 
development and tumorigenesis. 
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6.4 MiRNAs associated with Glioblastoma 
 
A systematic review reported that 253 miRNAs were found to be significantly upregulated 
and 95 miRNAs downregulated in GBM (Moller et al., 2013). Target genes of these miRNAs are 
implicated in many cancer-associated processes, such as cell proliferation, cell cycle regulation, 
apoptosis, autophagy, drug resistance, angiogenesis, invasion and metastasis (Banelli et al., 2017; 
Luo et al., 2015).  
For example, a significant decrease in the levels of miR-145 is not only observed in reactive 
astrocytes (see above), but also in astrocytic tumors, and it is correlated with poor prognosis in 
GBM patients (Lee et al., 2013a) and also inhibits glioma cell migration and self-renewal (Lee et 
al., 2013a; Lee et al., 2013b). The latter is consistent with experiments in hESCs where increased 
levels of miR-145 inhibit self-renewal (Xu et al., 2009). In addition, OCT4, a miR-145 target, is 
expressed in human gliomas and OCT4 protein levels correlate with increasing glioma grade (Du 
et al., 2009). 
In addition to its role in regulating astrocytic responses following SCI (see above), elevated 
levels of miR-21 were found in various types of cancer, including GBM (Akers et al., 2013). MiR-
21 promotion of cancer growth (Chung et al., 2013; Yang et al., 2014) depends on STAT3 (Loffler 
et al., 2007). Could miR-21 represent a link in the transition from reactive astrogliosis to brain 
tumorigenesis? Reactive astrocytes might upregulate miR-21, thereby acquiring persistent stem 
cell characteristics leading to uncontrolled cell proliferation, growth and ultimately resulting in 
malignancy. The identification of molecular pathways which contribute to the transition from 
reactive astrocytes to neoplastic cells may pave the way to the development of anti-tumorigenic 
therapies. 
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7. Conclusions and perspectives 
 
Astrocytes are implicated in the orchestration of neural development and constitute 
essential regulators of brain functions both in health and disease. Coordinated astrocyte 
differentiation is critical during development, and dysfunction of astrocytes can lead to several 
brain disorders. In the presence of a CNS insult, astrocytes respond by altering their morphology 
and molecular profile. Notably, they are able to be reprogrammed to a stem cell-like state 
permitting their eventual transdifferentiation into neurons or oligodendrocytes, which might be 
harnessed to restore brain damage. These processes rely on widespread transcriptional and 
epigenetic modifications that act in a highly coordinated manner leading to a fine balance between 
a healthy and pathological state.  
So far, the (de)differentiation potential of reactive astrocytes has been mainly characterized 
in vitro, based on experimental tractability and the ease of monitoring the role of specific growth 
factors favoring commitment to specific lineages, a task that is much more difficult within the 
complex cellular milieu of the brain. However, the capacity of astrocytes per se to dedifferentiate 
holds significant promise in developing endogenous brain repair strategies. Studying astrocyte 
plasticity and exploring the means that will allow such a switch of cellular fate in vivo, will provide 
new opportunities to implement novel endogenous therapeutic approaches. The ease of 
manipulation of 2D astrocyte cultures has provided the first vital mechanistic insight into their 
plasticity, but more complex cell systems that better recapitulate the cellular complexity of the 
brain will be necessary to fully understand the intricate relationship between signaling, 
transcriptome and epigenome that ultimately drive their phenotypic response in vivo. For example, 
3D cell culture using microfluidic devices or brain organoids may represent a valuable compromise 
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between in vitro and in vivo approaches, which will allow us to study the effect of other CNS cell 
types on astrocyte programs. Using these systems, it will be possible to study transcriptional and 
epigenetic changes in astrocytes to analyze, for example, the effect of familial AD or PD mutations. 
Screening compounds in a 3D system that show a specificity for differentially expressed epigenetic 
modulators in astrocytes may allow us to identify promising therapeutic treatments.  
Apart from the identification of epigenetic drugs which usually shows a lack of selectivity, 
another arising and promising approach is the targeted epigenome editing that enables a precise 
alteration in the epigenome. For example, designer methyltransferases can be constructed to 
achieve targeted methylation of a gene promoter (Siddique et al., 2013). Furthermore, by using the 
deactivated Cas9 (dCas9) nuclease in combination with the catalytic domain of a DNMT, it is 
possible to enable targeted CpG methylation of single or even multiple CpG sites, with the DNA 
methylation activity being heritable across mitotic divisions (Vojta et al., 2016). On the other hand, 
the dCas9 system can be used for targeted DNA demethylation of specific genomic loci (Xu et al., 
2016). In this way, the induced methylation/demethylation silences or activates, respectively, the 
expression of the target gene and may represent a potential locus-specific therapeutic strategy of 
the epigenome. For example, dCas9:Tet1 was recently used to target demethylation of a specific 
STAT3-binding site upstream of the Gfap promoter resulting in decreased methylation of the 
promoter and flanking region accompanied by increased Gfap expression (Morita et al., 2016).   
Another critical, and often underappreciated feature of astrocytes is their heterogeneity. 
Due to their multiple roles in the CNS it would not be surprising to uncover the existence of several 
astrocytic subpopulations, each displaying specific properties and functions. To fully understand 
the extent, studies including transcriptomics combined with chromatin accessibility and 
proteomics analyses at single cell resolution will be crucial. In fact, methods that utilize average 
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responses of a cell population are not able to detect subtle differences across individual cells. 
Applying single-cell techniques, for example in homeostatic and reactive astrocytes, will provide 
pivotal information on their cellular state under specific conditions. In addition, single-cell 
analyses will highlight any heterogeneity within the different brain regions and reveal the existence 
of possible astrocytic subpopulations. Such data will allow to infer the functional states of the 
identified cellular diversity and to understand the fate of specific subpopulation of astrocytes under 
homeostatic and pathological conditions. Such analyses are beginning to emerge and, for example, 
single-cell transcriptomic analysis of the adult NSC lineage revealed their existence on a 
continuum through the processes of activation and differentiation (Dulken et al., 2017). 
In the last few years, more consideration has been given to the roles and potential 
therapeutic contribution of non-coding RNAs. For example, the long non-coding RNA (lncRNA) 
MALAT1, secreted by transplanted adipose-derived stem cells, has been shown to exert 
neuroprotective effects and ameliorate motor and cognitive impairments in a TBI mouse model. 
In the absence of MALAT1, both motor and cognitive improvements were prevented and neuronal 
loss was not reduced (Tajiri et al., 2014). Transcriptional analyses of the brain tissue in a TBI rat 
model revealed that inflammatory, cell cycle, cell death, and regenerative molecular pathways are 
dependent on MALAT1 modulation, reinforcing the therapeutic potential of this lncRNA (Patel et 
al., 2018). Similar studies conducted in NSCs or astrocytes may reveal important aspects of the 
lncRNAs in these cells unveiling potential therapeutic applications of these molecules.    
There are clearly many parallels between the signaling, transcriptional and epigenetic 
mechanisms guiding astrocyte development and those that regulate astrocyte pathology. It is this 
commonality of mechanism that underwrites the possibility of identifying therapeutic mechanisms 
in neurodegeneration and tumorigenesis. For the latter, this approach would result particularly 
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relevant, where the identification of novel developmental factors influencing the molecular and 
cellular astrocytic identities would enable adopting new approaches in the context of the 
differentiation therapy (Laug et al., 2018), as attempts towards this direction have not been 
prosperous so far. Efforts to induce cell cycle arrest and differentiation of GSCs conducted in vitro, 
revealed that only a subset of GSCs responded the desired way. The cells still remained vulnerable 
to re-enter cell cycle and dedifferentiate as the differentiation-accompanied epigenetic 
modifications were not complete (Caren et al., 2015). Therefore, caution must be exerted since 
these overtly differentiated cells still retain the potential to re-acquire their old identity and become 
once more tumorigenic. Single cell genetic fate mapping of the differentiated GSCs will allow to 
identify which of these cells truly altered their epigenome and gene expression profile towards a 
non-proliferating and mature cell type. In this way, it may be possible to select specific 
subpopulations for further usage in therapeutic applications. From a different perspective, 
genetically engineered human NSCs have been successfully transplanted into mice bearing brain 
metastases from lung cancer where they were able to target and inhibit tumor growth. In this study, 
the NSCs were essentially acting as transient drug delivery vehicles, by converting a pro-drug into 
its cytotoxic form that preferentially targeted dividing cells and then undergoing programmed cell 
death (Hong et al., 2013). Thus, NSC strategies employed to arrest aberrant cell proliferation could 
also be considered in brain tumor therapies. 
Although an increasing number of studies implicate specific epigenetic events with 
gliomagenesis, further research is needed to fully comprehend their role in tumor initiation, 
progression and recurrence. In this way, biomarkers of diagnostic and prognostic value can be 
identified together with derivation of new tools to manipulate the epigenome of the patients 
potentially opening new avenues for GBM treatment. Pharmacological intervention on DNA 
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methylation and histone acetylation has been broadly exploited in tumor biology with some 
compounds showing promise as tools to combat cancer. However, only few are approved by the 
US FDA and they have serious limitations. For example, HDAC inhibitors target only a small 
percentage of all acetylation sites, indicating that there is still room for improvement and large-
scale screenings and trials will be needed to identify novel lead compounds. The construction of 
target specific drugs, i.e. intervening with a unique acetylation, methylation event or selective 
inhibition of specific HDACs and DNMTs is a highly demanding task but, if successful, it will 
reduce the side effects that occur with global inhibition of these epigenetic modulators. 
Identification of the genome-wide DNA methylation profile of patients with glioma tumors is 
becoming relatively straightforward (Capper et al., 2018). Characterizing the methylome of these 
patients may enable physicians to utilize personalized medicine approaches and make informed 
choices on the potential efficacy of therapeutic agents that target DNA methylation. Pharmaco-
epigenomics is an emerging field that makes use of epigenetic processes that underpin CNS 
diseases. The ability to use individuals’ epigenetic profiles in order to identify sensitivity or 
resistance to existing drugs, represents a valuable tool in the emerging field of personalized 
medicine. In addition, these advances allow a theranostic strategy whereby changes in the 
epigenome can be monitored during the course of treatment to provide a dynamic biomarker of 
drug efficiency and disease progression.  
Taken together, it is evident that, in astrocytes, epigenetic mechanisms, such as DNA 
methylation and histone modifications, are extremely complex and their causative role in 
pathological conditions is still a matter of investigation. However, it is clear that a deep molecular 
understanding of their mechanism of action will bridge the gap between extrinsic and intrinsic 
factors that drive change of astrocytes identity as well as to shed light on their involvement in brain 
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disease. Understanding how these various mechanisms eventually alter gene expression and define 
or re-define astrocytic cell fate is critically important. Not only will it unveil neurodevelopmental 
mechanisms, but it will also provide the knowledge base to exploit these processes to manipulate 
astrocytes in vivo, thereby paving the way to novel therapies for multiple CNS disorders.  
 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
52 
 
Acknowledgements  
 
M.A.S.P. and L.G. were supported by the University of Luxembourg (IRP ASTROSYS). A.M. 
was supported by the Luxembourg Institute of Health and the Luxembourg Centre for Systems 
Biomedicine (MIGLISYS). 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
53 
 
References 
 
A., B., DORIS, D., 1976. THE ASTROGLIAL RESPONSE TO STABBING. IMMUNOFLUORESCENCE STUDIES 
WITH ANTIBODIES TO ASTROCYTE‐SPECIFIC PROTEIN (GFA) IN MAMMALIAN AND 
SUBMAMMALIAN VERTEBRATES. Neuropathology and Applied Neurobiology 2, 99-110. 
Ahmed, A.U., Auffinger, B., Lesniak, M.S., 2013. Understanding glioma stem cells: rationale, clinical 
relevance and therapeutic strategies. Expert review of neurotherapeutics 13, 545-555. 
Akers, J.C., Ramakrishnan, V., Kim, R., Skog, J., Nakano, I., Pingle, S., Kalinina, J., Hua, W., Kesari, S., Mao, 
Y., Breakefield, X.O., Hochberg, F.H., Van Meir, E.G., Carter, B.S., Chen, C.C., 2013. MiR-21 in the 
extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker 
development. PloS one 8, e78115. 
Alunni, A., Bally-Cuif, L., 2016. A comparative view of regenerative neurogenesis in vertebrates. 
Development 143, 741-753. 
Anderson, M.A., Ao, Y., Sofroniew, M.V., 2014. Heterogeneity of reactive astrocytes. Neuroscience letters 
565, 23-29. 
Andersson, E.R., Sandberg, R., Lendahl, U., 2011. Notch signaling: simplicity in design, versatility in 
function. Development 138, 3593-3612. 
Aravantinou-Fatorou, K., Ortega, F., Chroni-Tzartou, D., Antoniou, N., Poulopoulou, C., Politis, P.K., 
Berninger, B., Matsas, R., Thomaidou, D., 2015. CEND1 and NEUROGENIN2 Reprogram Mouse 
Astrocytes and Embryonic Fibroblasts to Induced Neural Precursors and Differentiated Neurons. 
Stem cell reports 5, 405-418. 
Arenas, E., 2014. Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine 
for Parkinson's disease. Journal of molecular cell biology 6, 42-53. 
Asano, H., Aonuma, M., Sanosaka, T., Kohyama, J., Namihira, M., Nakashima, K., 2009. Astrocyte 
differentiation of neural precursor cells is enhanced by retinoic acid through a change in 
epigenetic modification. Stem cells 27, 2744-2752. 
Baeza, N., Weller, M., Yonekawa, Y., Kleihues, P., Ohgaki, H., 2003. PTEN methylation and expression in 
glioblastomas. Acta neuropathologica 106, 479-485. 
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., von Deimling, A., 2008. Analysis of the IDH1 
codon 132 mutation in brain tumors. Acta neuropathologica 116, 597-602. 
Banelli, B., Forlani, A., Allemanni, G., Morabito, A., Pistillo, M.P., Romani, M., 2017. MicroRNA in 
Glioblastoma: An Overview. International journal of genomics 2017, 7639084. 
Barcia, C., Guillemin, G.J., Curtin, J.F., Zirger, J.M., 2016. Editorial: Glial Cells: Managers of Neuro-
Immunity. Frontiers in cellular neuroscience 10, 60. 
Bardehle, S., Kruger, M., Buggenthin, F., Schwausch, J., Ninkovic, J., Clevers, H., Snippert, H.J., Theis, F.J., 
Meyer-Luehmann, M., Bechmann, I., Dimou, L., Gotz, M., 2013. Live imaging of astrocyte 
responses to acute injury reveals selective juxtavascular proliferation. Nature neuroscience 16, 
580-586. 
Barres, B.A., 2008. The mystery and magic of glia: a perspective on their roles in health and disease. 
Neuron 60, 430-440. 
Beebe, K., Lee, W.C., Micchelli, C.A., 2010. JAK/STAT signaling coordinates stem cell proliferation and 
multilineage differentiation in the Drosophila intestinal stem cell lineage. Developmental biology 
338, 28-37. 
Ben Haim, L., Carrillo-de Sauvage, M.A., Ceyzeriat, K., Escartin, C., 2015. Elusive roles for reactive 
astrocytes in neurodegenerative diseases. Frontiers in cellular neuroscience 9, 278. 
Bender, S., Tang, Y., Lindroth, A.M., Hovestadt, V., Jones, D.T., Kool, M., Zapatka, M., Northcott, P.A., 
Sturm, D., Wang, W., Radlwimmer, B., Hojfeldt, J.W., Truffaux, N., Castel, D., Schubert, S., 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
54 
 
Ryzhova, M., Seker-Cin, H., Gronych, J., Johann, P.D., Stark, S., Meyer, J., Milde, T., Schuhmann, 
M., Ebinger, M., Monoranu, C.M., Ponnuswami, A., Chen, S., Jones, C., Witt, O., Collins, V.P., von 
Deimling, A., Jabado, N., Puget, S., Grill, J., Helin, K., Korshunov, A., Lichter, P., Monje, M., Plass, 
C., Cho, Y.J., Pfister, S.M., 2013. Reduced H3K27me3 and DNA hypomethylation are major drivers 
of gene expression in K27M mutant pediatric high-grade gliomas. Cancer cell 24, 660-672. 
Berninger, B., Costa, M.R., Koch, U., Schroeder, T., Sutor, B., Grothe, B., Gotz, M., 2007. Functional 
properties of neurons derived from in vitro reprogrammed postnatal astroglia. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 27, 8654-8664. 
Berwick, D.C., Harvey, K., 2014. The regulation and deregulation of Wnt signaling by PARK genes in health 
and disease. Journal of molecular cell biology 6, 3-12. 
Bhalala, O.G., Pan, L., Sahni, V., McGuire, T.L., Gruner, K., Tourtellotte, W.G., Kessler, J.A., 2012. microRNA-
21 regulates astrocytic response following spinal cord injury. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 32, 17935-17947. 
Bi, F., Huang, C., Tong, J., Qiu, G., Huang, B., Wu, Q., Li, F., Xu, Z., Bowser, R., Xia, X.G., Zhou, H., 2013. 
Reactive astrocytes secrete lcn2 to promote neuron death. Proceedings of the National Academy 
of Sciences of the United States of America 110, 4069-4074. 
Birck, C., Koncina, E., Heurtaux, T., Glaab, E., Michelucci, A., Heuschling, P., Grandbarbe, L., 2016. 
Transcriptomic analyses of primary astrocytes under TNFalpha treatment. Genomics data 7, 7-11. 
Bird, A., 2002. DNA methylation patterns and epigenetic memory. Genes & development 16, 6-21. 
Blanc, J.L., Wager, M., Guilhot, J., Kusy, S., Bataille, B., Chantereau, T., Lapierre, F., Larsen, C.J., Karayan-
Tapon, L., 2004. Correlation of clinical features and methylation status of MGMT gene promoter 
in glioblastomas. Journal of neuro-oncology 68, 275-283. 
Bonni, A., Sun, Y., Nadal-Vicens, M., Bhatt, A., Frank, D.A., Rozovsky, I., Stahl, N., Yancopoulos, G.D., 
Greenberg, M.E., 1997. Regulation of gliogenesis in the central nervous system by the JAK-STAT 
signaling pathway. Science 278, 477-483. 
Borggrefe, T., Oswald, F., 2009. The Notch signaling pathway: transcriptional regulation at Notch target 
genes. Cellular and molecular life sciences : CMLS 66, 1631-1646. 
Bouvier, D.S., Jones, E.V., Quesseveur, G., Davoli, M.A., T, A.F., Quirion, R., Mechawar, N., Murai, K.K., 
2016. High Resolution Dissection of Reactive Glial Nets in Alzheimer's Disease. Scientific reports 
6, 24544. 
Brambilla, R., Bracchi-Ricard, V., Hu, W.H., Frydel, B., Bramwell, A., Karmally, S., Green, E.J., Bethea, J.R., 
2005. Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional 
recovery after spinal cord injury. The Journal of experimental medicine 202, 145-156. 
Brown, D.R., 1999. Neurons depend on astrocytes in a coculture system for protection from glutamate 
toxicity. Molecular and cellular neurosciences 13, 379-389. 
Buffo, A., Rite, I., Tripathi, P., Lepier, A., Colak, D., Horn, A.P., Mori, T., Gotz, M., 2008. Origin and progeny 
of reactive gliosis: A source of multipotent cells in the injured brain. Proceedings of the National 
Academy of Sciences of the United States of America 105, 3581-3586. 
Cadieux, B., Ching, T.T., VandenBerg, S.R., Costello, J.F., 2006. Genome-wide hypomethylation in human 
glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate 
reductase allele status, and increased proliferation. Cancer research 66, 8469-8476. 
Capper, D., Jones, D.T.W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, 
L., Reuss, D.E., Kratz, A., Wefers, A.K., Huang, K., Pajtler, K.W., Schweizer, L., Stichel, D., Olar, A., 
Engel, N.W., Lindenberg, K., Harter, P.N., Braczynski, A.K., Plate, K.H., Dohmen, H., Garvalov, B.K., 
Coras, R., Holsken, A., Hewer, E., Bewerunge-Hudler, M., Schick, M., Fischer, R., Beschorner, R., 
Schittenhelm, J., Staszewski, O., Wani, K., Varlet, P., Pages, M., Temming, P., Lohmann, D., Selt, F., 
Witt, H., Milde, T., Witt, O., Aronica, E., Giangaspero, F., Rushing, E., Scheurlen, W., Geisenberger, 
C., Rodriguez, F.J., Becker, A., Preusser, M., Haberler, C., Bjerkvig, R., Cryan, J., Farrell, M., Deckert, 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
55 
 
M., Hench, J., Frank, S., Serrano, J., Kannan, K., Tsirigos, A., Bruck, W., Hofer, S., Brehmer, S., Seiz-
Rosenhagen, M., Hanggi, D., Hans, V., Rozsnoki, S., Hansford, J.R., Kohlhof, P., Kristensen, B.W., 
Lechner, M., Lopes, B., Mawrin, C., Ketter, R., Kulozik, A., Khatib, Z., Heppner, F., Koch, A., Jouvet, 
A., Keohane, C., Muhleisen, H., Mueller, W., Pohl, U., Prinz, M., Benner, A., Zapatka, M., Gottardo, 
N.G., Driever, P.H., Kramm, C.M., Muller, H.L., Rutkowski, S., von Hoff, K., Fruhwald, M.C., 
Gnekow, A., Fleischhack, G., Tippelt, S., Calaminus, G., Monoranu, C.M., Perry, A., Jones, C., 
Jacques, T.S., Radlwimmer, B., Gessi, M., Pietsch, T., Schramm, J., Schackert, G., Westphal, M., 
Reifenberger, G., Wesseling, P., Weller, M., Collins, V.P., Blumcke, I., Bendszus, M., Debus, J., 
Huang, A., Jabado, N., Northcott, P.A., Paulus, W., Gajjar, A., Robinson, G.W., Taylor, M.D., 
Jaunmuktane, Z., Ryzhova, M., Platten, M., Unterberg, A., Wick, W., Karajannis, M.A., Mittelbronn, 
M., Acker, T., Hartmann, C., Aldape, K., Schuller, U., Buslei, R., Lichter, P., Kool, M., Herold-Mende, 
C., Ellison, D.W., Hasselblatt, M., Snuderl, M., Brandner, S., Korshunov, A., von Deimling, A., 
Pfister, S.M., 2018. DNA methylation-based classification of central nervous system tumours. 
Nature 555, 469-474. 
Caren, H., Stricker, S.H., Bulstrode, H., Gagrica, S., Johnstone, E., Bartlett, T.E., Feber, A., Wilson, G., 
Teschendorff, A.E., Bertone, P., Beck, S., Pollard, S.M., 2015. Glioblastoma Stem Cells Respond to 
Differentiation Cues but Fail to Undergo Commitment and Terminal Cell-Cycle Arrest. Stem cell 
reports 5, 829-842. 
Carlen, M., Meletis, K., Goritz, C., Darsalia, V., Evergren, E., Tanigaki, K., Amendola, M., Barnabe-Heider, 
F., Yeung, M.S., Naldini, L., Honjo, T., Kokaia, Z., Shupliakov, O., Cassidy, R.M., Lindvall, O., Frisen, 
J., 2009. Forebrain ependymal cells are Notch-dependent and generate neuroblasts and 
astrocytes after stroke. Nature neuroscience 12, 259-267. 
Cate, H.S., Sabo, J.K., Merlo, D., Kemper, D., Aumann, T.D., Robinson, J., Merson, T.D., Emery, B., Perreau, 
V.M., Kilpatrick, T.J., 2010. Modulation of bone morphogenic protein signalling alters numbers of 
astrocytes and oligodendroglia in the subventricular zone during cuprizone-induced 
demyelination. Journal of neurochemistry 115, 11-22. 
Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T.S., Salama, S.R., Murray, B.A., Morozova, O., Newton, 
Y., Radenbaugh, A., Pagnotta, S.M., Anjum, S., Wang, J., Manyam, G., Zoppoli, P., Ling, S., Rao, 
A.A., Grifford, M., Cherniack, A.D., Zhang, H., Poisson, L., Carlotti, C.G., Jr., Tirapelli, D.P., Rao, A., 
Mikkelsen, T., Lau, C.C., Yung, W.K., Rabadan, R., Huse, J., Brat, D.J., Lehman, N.L., Barnholtz-Sloan, 
J.S., Zheng, S., Hess, K., Rao, G., Meyerson, M., Beroukhim, R., Cooper, L., Akbani, R., Wrensch, 
M., Haussler, D., Aldape, K.D., Laird, P.W., Gutmann, D.H., Network, T.R., Noushmehr, H., 
Iavarone, A., Verhaak, R.G., 2016. Molecular Profiling Reveals Biologically Discrete Subsets and 
Pathways of Progression in Diffuse Glioma. Cell 164, 550-563. 
Chan, K.M., Fang, D., Gan, H., Hashizume, R., Yu, C., Schroeder, M., Gupta, N., Mueller, S., James, C.D., 
Jenkins, R., Sarkaria, J., Zhang, Z., 2013. The histone H3.3K27M mutation in pediatric glioma 
reprograms H3K27 methylation and gene expression. Genes & development 27, 985-990. 
Chen, Y., Vartiainen, N.E., Ying, W., Chan, P.H., Koistinaho, J., Swanson, R.A., 2001. Astrocytes protect 
neurons from nitric oxide toxicity by a glutathione-dependent mechanism. Journal of 
neurochemistry 77, 1601-1610. 
Cheng, P.Y., Lin, Y.P., Chen, Y.L., Lee, Y.C., Tai, C.C., Wang, Y.T., Chen, Y.J., Kao, C.F., Yu, J., 2011. Interplay 
between SIN3A and STAT3 mediates chromatin conformational changes and GFAP expression 
during cellular differentiation. PloS one 6, e22018. 
Chien, C.S., Wang, M.L., Chu, P.Y., Chang, Y.L., Liu, W.H., Yu, C.C., Lan, Y.T., Huang, P.I., Lee, Y.Y., Chen, 
Y.W., Lo, W.L., Chiou, S.H., 2015. Lin28B/Let-7 Regulates Expression of Oct4 and Sox2 and 
Reprograms Oral Squamous Cell Carcinoma Cells to a Stem-like State. Cancer research 75, 2553-
2565. 
AC
CE
PT
E
 M
AN
US
RI
PT
Pavlou et al.  Progress in Neurobiology 
56 
 
Chowdhury, R., Yeoh, K.K., Tian, Y.M., Hillringhaus, L., Bagg, E.A., Rose, N.R., Leung, I.K., Li, X.S., Woon, 
E.C., Yang, M., McDonough, M.A., King, O.N., Clifton, I.J., Klose, R.J., Claridge, T.D., Ratcliffe, P.J., 
Schofield, C.J., Kawamura, A., 2011. The oncometabolite 2-hydroxyglutarate inhibits histone 
lysine demethylases. EMBO reports 12, 463-469. 
Chung, W.M., Chang, W.C., Chen, L., Chang, Y.Y., Shyr, C.R., Hung, Y.C., Ma, W.L., 2013. MicroRNA-21 
promotes the ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor 
populations in vitro. Stem cell research & therapy 4, 88. 
Clarke, L.E., Liddelow, S.A., Chakraborty, C., Munch, A.E., Heiman, M., Barres, B.A., 2018. Normal aging 
induces A1-like astrocyte reactivity. Proceedings of the National Academy of Sciences of the 
United States of America 115, E1896-E1905. 
Colodner, K.J., Montana, R.A., Anthony, D.C., Folkerth, R.D., De Girolami, U., Feany, M.B., 2005. 
Proliferative potential of human astrocytes. Journal of neuropathology and experimental 
neurology 64, 163-169. 
Costello, J.F., Berger, M.S., Huang, H.S., Cavenee, W.K., 1996. Silencing of p16/CDKN2 expression in human 
gliomas by methylation and chromatin condensation. Cancer research 56, 2405-2410. 
Del Sol, A., Buckley, N.J., 2014. Concise review: a population shift view of cellular reprogramming. Stem 
cells 32, 1367-1372. 
Domingues, H.S., Portugal, C.C., Socodato, R., Relvas, J.B., 2016. Oligodendrocyte, Astrocyte, and Microglia 
Crosstalk in Myelin Development, Damage, and Repair. Frontiers in cell and developmental biology 
4, 71. 
Du, Z., Jia, D., Liu, S., Wang, F., Li, G., Zhang, Y., Cao, X., Ling, E.A., Hao, A., 2009. Oct4 is expressed in 
human gliomas and promotes colony formation in glioma cells. Glia 57, 724-733. 
Dulken, B.W., Leeman, D.S., Boutet, S.C., Hebestreit, K., Brunet, A., 2017. Single-Cell Transcriptomic 
Analysis Defines Heterogeneity and Transcriptional Dynamics in the Adult Neural Stem Cell 
Lineage. Cell reports 18, 777-790. 
Elneihoum, A.M., Falke, P., Axelsson, L., Lundberg, E., Lindgarde, F., Ohlsson, K., 1996. Leukocyte 
activation detected by increased plasma levels of inflammatory mediators in patients with 
ischemic cerebrovascular diseases. Stroke 27, 1734-1738. 
Eng, L.F., Vanderhaeghen, J.J., Bignami, A., Gerstl, B., 1971. An acidic protein isolated from fibrous 
astrocytes. Brain research 28, 351-354. 
Escartin, C., Pierre, K., Colin, A., Brouillet, E., Delzescaux, T., Guillermier, M., Dhenain, M., Deglon, N., 
Hantraye, P., Pellerin, L., Bonvento, G., 2007. Activation of astrocytes by CNTF induces metabolic 
plasticity and increases resistance to metabolic insults. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 27, 7094-7104. 
Faiz, M., Sachewsky, N., Gascon, S., Bang, K.W., Morshead, C.M., Nagy, A., 2015. Adult Neural Stem Cells 
from the Subventricular Zone Give Rise to Reactive Astrocytes in the Cortex after Stroke. Cell stem 
cell 17, 624-634. 
Fan, G., Martinowich, K., Chin, M.H., He, F., Fouse, S.D., Hutnick, L., Hattori, D., Ge, W., Shen, Y., Wu, H., 
ten Hoeve, J., Shuai, K., Sun, Y.E., 2005. DNA methylation controls the timing of astrogliogenesis 
through regulation of JAK-STAT signaling. Development 132, 3345-3356. 
Faulkner, J.R., Herrmann, J.E., Woo, M.J., Tansey, K.E., Doan, N.B., Sofroniew, M.V., 2004. Reactive 
astrocytes protect tissue and preserve function after spinal cord injury. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 24, 2143-2155. 
Fiore, R., Khudayberdiev, S., Saba, R., Schratt, G., 2011. MicroRNA function in the nervous system. 
Progress in molecular biology and translational science 102, 47-100. 
Follert, P., Cremer, H., Beclin, C., 2014. MicroRNAs in brain development and function: a matter of 
flexibility and stability. Frontiers in molecular neuroscience 7, 5. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
57 
 
Friedmann-Morvinski, D., Bushong, E.A., Ke, E., Soda, Y., Marumoto, T., Singer, O., Ellisman, M.H., Verma, 
I.M., 2012. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. 
Science 338, 1080-1084. 
Friedmann-Morvinski, D., Verma, I.M., 2014. Dedifferentiation and reprogramming: origins of cancer stem 
cells. EMBO reports 15, 244-253. 
Gabel, S., Koncina, E., Dorban, G., Heurtaux, T., Birck, C., Glaab, E., Michelucci, A., Heuschling, P., 
Grandbarbe, L., 2016. Inflammation Promotes a Conversion of Astrocytes into Neural Progenitor 
Cells via NF-kappaB Activation. Molecular neurobiology 53, 5041-5055. 
Gadea, A., Schinelli, S., Gallo, V., 2008. Endothelin-1 regulates astrocyte proliferation and reactive gliosis 
via a JNK/c-Jun signaling pathway. The Journal of neuroscience : the official journal of the Society 
for Neuroscience 28, 2394-2408. 
Gaiano, N., Nye, J.S., Fishell, G., 2000. Radial glial identity is promoted by Notch1 signaling in the murine 
forebrain. Neuron 26, 395-404. 
Gao, K., Wang, C.R., Jiang, F., Wong, A.Y., Su, N., Jiang, J.H., Chai, R.C., Vatcher, G., Teng, J., Chen, J., Jiang, 
Y.W., Yu, A.C., 2013. Traumatic scratch injury in astrocytes triggers calcium influx to activate the 
JNK/c-Jun/AP-1 pathway and switch on GFAP expression. Glia 61, 2063-2077. 
Gao, Y., Guan, M., Su, B., Liu, W., Xu, M., Lu, Y., 2004. Hypermethylation of the RASSF1A gene in gliomas. 
Clinica chimica acta; international journal of clinical chemistry 349, 173-179. 
Gascon, S., Masserdotti, G., Russo, G.L., Gotz, M., 2017. Direct Neuronal Reprogramming: Achievements, 
Hurdles, and New Roads to Success. Cell stem cell 21, 18-34. 
Glushakova, O.Y., Glushakov, A.O., Borlongan, C.V., Valadka, A.B., Hayes, R.L., Glushakov, A.V., 2018. Role 
of Caspase-3-Mediated Apoptosis in Chronic Caspase-3-Cleaved Tau Accumulation and Blood-
Brain Barrier Damage in the Corpus Callosum after Traumatic Brain Injury in Rats. Journal of 
neurotrauma 35, 157-173. 
Gotz, M., Sirko, S., Beckers, J., Irmler, M., 2015. Reactive astrocytes as neural stem or progenitor cells: In 
vivo lineage, In vitro potential, and Genome-wide expression analysis. Glia 63, 1452-1468. 
Graff, J., Mansuy, I.M., 2008. Epigenetic codes in cognition and behaviour. Behav Brain Res 192, 70-87. 
Grandbarbe, L., Bouissac, J., Rand, M., Hrabe de Angelis, M., Artavanis-Tsakonas, S., Mohier, E., 2003. 
Delta-Notch signaling controls the generation of neurons/glia from neural stem cells in a stepwise 
process. Development 130, 1391-1402. 
Guo, Z., Zhang, L., Wu, Z., Chen, Y., Wang, F., Chen, G., 2014. In vivo direct reprogramming of reactive glial 
cells into functional neurons after brain injury and in an Alzheimer's disease model. Cell stem cell 
14, 188-202. 
Hara, M., Kobayakawa, K., Ohkawa, Y., Kumamaru, H., Yokota, K., Saito, T., Kijima, K., Yoshizaki, S., 
Harimaya, K., Nakashima, Y., Okada, S., 2017. Interaction of reactive astrocytes with type I 
collagen induces astrocytic scar formation through the integrin-N-cadherin pathway after spinal 
cord injury. Nature medicine 23, 818-828. 
Hatada, I., Namihira, M., Morita, S., Kimura, M., Horii, T., Nakashima, K., 2008. Astrocyte-specific genes 
are generally demethylated in neural precursor cells prior to astrocytic differentiation. PloS one 
3, e3189. 
Heinrich, C., Blum, R., Gascon, S., Masserdotti, G., Tripathi, P., Sanchez, R., Tiedt, S., Schroeder, T., Gotz, 
M., Berninger, B., 2010. Directing astroglia from the cerebral cortex into subtype specific 
functional neurons. PLoS biology 8, e1000373. 
Herrmann, J.E., Imura, T., Song, B., Qi, J., Ao, Y., Nguyen, T.K., Korsak, R.A., Takeda, K., Akira, S., Sofroniew, 
M.V., 2008. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. 
The Journal of neuroscience : the official journal of the Society for Neuroscience 28, 7231-7243. 
Hirabayashi, Y., Gotoh, Y., 2005. Stage-dependent fate determination of neural precursor cells in mouse 
forebrain. Neurosci Res 51, 331-336. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
58 
 
Hong, S.H., Lee, H.J., An, J., Lim, I., Borlongan, C., Aboody, K.S., Kim, S.U., 2013. Human neural stem cells 
expressing carboxyl esterase target and inhibit tumor growth of lung cancer brain metastases. 
Cancer gene therapy 20, 678-682. 
Howng, S.Y., Huang, Y., Ptacek, L., Fu, Y.H., 2015. Understanding the role of dicer in astrocyte 
development. PloS one 10, e0126667. 
Hutchison, E.R., Kawamoto, E.M., Taub, D.D., Lal, A., Abdelmohsen, K., Zhang, Y., Wood, W.H., 3rd, 
Lehrmann, E., Camandola, S., Becker, K.G., Gorospe, M., Mattson, M.P., 2013. Evidence for miR-
181 involvement in neuroinflammatory responses of astrocytes. Glia 61, 1018-1028. 
Imayoshi, I., Sakamoto, M., Yamaguchi, M., Mori, K., Kageyama, R., 2010. Essential roles of Notch signaling 
in maintenance of neural stem cells in developing and adult brains. The Journal of neuroscience : 
the official journal of the Society for Neuroscience 30, 3489-3498. 
Inestrosa, N.C., Arenas, E., 2010. Emerging roles of Wnts in the adult nervous system. Nature reviews. 
Neuroscience 11, 77-86. 
Iwata-Ichikawa, E., Kondo, Y., Miyazaki, I., Asanuma, M., Ogawa, N., 1999. Glial cells protect neurons 
against oxidative stress via transcriptional up-regulation of the glutathione synthesis. Journal of 
neurochemistry 72, 2334-2344. 
Jin, M., Jang, E., Suk, K., 2014. Lipocalin-2 Acts as a Neuroinflammatogen in Lipopolysaccharide-injected 
Mice. Experimental neurobiology 23, 155-162. 
John Lin, C.C., Deneen, B., 2013. Astrocytes: the missing link in neurologic disease? Seminars in pediatric 
neurology 20, 236-241. 
Jones, C., Karajannis, M.A., Jones, D.T.W., Kieran, M.W., Monje, M., Baker, S.J., Becher, O.J., Cho, Y.J., 
Gupta, N., Hawkins, C., Hargrave, D., Haas-Kogan, D.A., Jabado, N., Li, X.N., Mueller, S., Nicolaides, 
T., Packer, R.J., Persson, A.I., Phillips, J.J., Simonds, E.F., Stafford, J.M., Tang, Y., Pfister, S.M., 
Weiss, W.A., 2017. Pediatric high-grade glioma: biologically and clinically in need of new thinking. 
Neuro-oncology 19, 153-161. 
Kalani, M.Y., Cheshier, S.H., Cord, B.J., Bababeygy, S.R., Vogel, H., Weissman, I.L., Palmer, T.D., Nusse, R., 
2008. Wnt-mediated self-renewal of neural stem/progenitor cells. Proceedings of the National 
Academy of Sciences of the United States of America 105, 16970-16975. 
Kanski, R., Sneeboer, M.A., van Bodegraven, E.J., Sluijs, J.A., Kropff, W., Vermunt, M.W., Creyghton, M.P., 
De Filippis, L., Vescovi, A., Aronica, E., van Tijn, P., van Strien, M.E., Hol, E.M., 2014. Histone 
acetylation in astrocytes suppresses GFAP and stimulates a reorganization of the intermediate 
filament network. Journal of cell science 127, 4368-4380. 
Karimi-Abdolrezaee, S., Billakanti, R., 2012. Reactive astrogliosis after spinal cord injury-beneficial and 
detrimental effects. Molecular neurobiology 46, 251-264. 
Kim, J.H., Ko, P.W., Lee, H.W., Jeong, J.Y., Lee, M.G., Kim, J.H., Lee, W.H., Yu, R., Oh, W.J., Suk, K., 2017. 
Astrocyte-derived lipocalin-2 mediates hippocampal damage and cognitive deficits in 
experimental models of vascular dementia. Glia 65, 1471-1490. 
Klose, R.J., Bird, A.P., 2006. Genomic DNA methylation: the mark and its mediators. Trends in biochemical 
sciences 31, 89-97. 
Kong, S.Y., Kim, W., Lee, H.R., Kim, H.J., 2017. The histone demethylase KDM5A is required for the 
repression of astrocytogenesis and regulated by the translational machinery in neural progenitor 
cells. FASEB journal : official publication of the Federation of American Societies for Experimental 
Biology. 
Kouzarides, T., 2007. Chromatin modifications and their function. Cell 128, 693-705. 
Kriaucionis, S., Heintz, N., 2009. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje 
neurons and the brain. Science 324, 929-930. 
Kroehne, V., Freudenreich, D., Hans, S., Kaslin, J., Brand, M., 2011. Regeneration of the adult zebrafish 
brain from neurogenic radial glia-type progenitors. Development 138, 4831-4841. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
59 
 
L'Episcopo, F., Tirolo, C., Testa, N., Caniglia, S., Morale, M.C., Cossetti, C., D'Adamo, P., Zardini, E., 
Andreoni, L., Ihekwaba, A.E., Serra, P.A., Franciotta, D., Martino, G., Pluchino, S., Marchetti, B., 
2011. Reactive astrocytes and Wnt/beta-catenin signaling link nigrostriatal injury to repair in 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiology of 
disease 41, 508-527. 
Lathia, J.D., Mack, S.C., Mulkearns-Hubert, E.E., Valentim, C.L., Rich, J.N., 2015. Cancer stem cells in 
glioblastoma. Genes & development 29, 1203-1217. 
Laug, D., Glasgow, S.M., Deneen, B., 2018. A glial blueprint for gliomagenesis. Nature reviews. 
Neuroscience 19, 393-403. 
Lee, H.K., Bier, A., Cazacu, S., Finniss, S., Xiang, C., Twito, H., Poisson, L.M., Mikkelsen, T., Slavin, S., Jacoby, 
E., Yalon, M., Toren, A., Rempel, S.A., Brodie, C., 2013a. MicroRNA-145 is downregulated in glial 
tumors and regulates glioma cell migration by targeting connective tissue growth factor. PloS one 
8, e54652. 
Lee, H.K., Finniss, S., Cazacu, S., Bucris, E., Ziv-Av, A., Xiang, C., Bobbitt, K., Rempel, S.A., Hasselbach, L., 
Mikkelsen, T., Slavin, S., Brodie, C., 2013b. Mesenchymal stem cells deliver synthetic microRNA 
mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. 
Oncotarget 4, 346-361. 
Lee, S., Kim, J.H., Kim, J.H., Seo, J.W., Han, H.S., Lee, W.H., Mori, K., Nakao, K., Barasch, J., Suk, K., 2011. 
Lipocalin-2 Is a chemokine inducer in the central nervous system: role of chemokine ligand 10 
(CXCL10) in lipocalin-2-induced cell migration. The Journal of biological chemistry 286, 43855-
43870. 
Lewis, P.W., Muller, M.M., Koletsky, M.S., Cordero, F., Lin, S., Banaszynski, L.A., Garcia, B.A., Muir, T.W., 
Becher, O.J., Allis, C.D., 2013. Inhibition of PRC2 activity by a gain-of-function H3 mutation found 
in pediatric glioblastoma. Science 340, 857-861. 
Li, F., Liu, X., Sampson, J.H., Bigner, D.D., Li, C.Y., 2016. Rapid Reprogramming of Primary Human 
Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors. Cancer research 76, 
5143-5150. 
Li, X., Zhang, J., Gao, L., McClellan, S., Finan, M.A., Butler, T.W., Owen, L.B., Piazza, G.A., Xi, Y., 2012. MiR-
181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell death 
and differentiation 19, 378-386. 
Liddelow, S.A., Guttenplan, K.A., Clarke, L.E., Bennett, F.C., Bohlen, C.J., Schirmer, L., Bennett, M.L., 
Munch, A.E., Chung, W.S., Peterson, T.C., Wilton, D.K., Frouin, A., Napier, B.A., Panicker, N., 
Kumar, M., Buckwalter, M.S., Rowitch, D.H., Dawson, V.L., Dawson, T.M., Stevens, B., Barres, B.A., 
2017. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481-487. 
Liu, Y., Miao, Q., Yuan, J., Han, S.e., Zhang, P., Li, S., Rao, Z., Zhao, W., Ye, Q., Geng, J., Zhang, X., Cheng, L., 
2015. <em>Ascl1</em> Converts Dorsal Midbrain Astrocytes into Functional Neurons <em>In 
Vivo</em>. The Journal of Neuroscience 35, 9336-9355. 
Loffler, D., Brocke-Heidrich, K., Pfeifer, G., Stocsits, C., Hackermuller, J., Kretzschmar, A.K., Burger, R., 
Gramatzki, M., Blumert, C., Bauer, K., Cvijic, H., Ullmann, A.K., Stadler, P.F., Horn, F., 2007. 
Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction 
of microRNA-21 through a highly conserved enhancer. Blood 110, 1330-1333. 
Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., 
Wiestler, O.D., Kleihues, P., Ellison, D.W., 2016. The 2016 World Health Organization Classification 
of Tumors of the Central Nervous System: a summary. Acta neuropathologica 131, 803-820. 
Louvi, A., Artavanis-Tsakonas, S., 2006. Notch signalling in vertebrate neural development. Nature 
reviews. Neuroscience 7, 93-102. 
AC
CE
PT
ED
 M
AN
US
CR
I T
Pavlou et al.  Progress in Neurobiology 
60 
 
Lozano, D., Gonzales-Portillo, G.S., Acosta, S., de la Pena, I., Tajiri, N., Kaneko, Y., Borlongan, C.V., 2015. 
Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and 
therapeutic opportunities. Neuropsychiatric disease and treatment 11, 97-106. 
Luo, J.W., Wang, X., Yang, Y., Mao, Q., 2015. Role of micro-RNA (miRNA) in pathogenesis of glioblastoma. 
European review for medical and pharmacological sciences 19, 1630-1639. 
Mabie, P.C., Mehler, M.F., Kessler, J.A., 1999. Multiple roles of bone morphogenetic protein signaling in 
the regulation of cortical cell number and phenotype. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 19, 7077-7088. 
Magnusson, J.P., Goritz, C., Tatarishvili, J., Dias, D.O., Smith, E.M., Lindvall, O., Kokaia, Z., Frisen, J., 2014. 
A latent neurogenic program in astrocytes regulated by Notch signaling in the mouse. Science 346, 
237-241. 
Maragakis, N.J., Rothstein, J.D., 2006. Mechanisms of Disease: astrocytes in neurodegenerative disease. 
Nature clinical practice. Neurology 2, 679-689. 
McIver  Sally R. , F.M., and Haydon  Philip G. 2013. Astrocyte–Neuron Communications. In: Neural-Immune 
Interactions in Brain Function and Alcohol Related Disorders 
pp. 31-64. Ed. C.C.G. Noronha. Springer, Boston, MA. 
Meares, G.P., Rajbhandari, R., Gerigk, M., Tien, C.L., Chang, C., Fehling, S.C., Rowse, A., Mulhern, K.C., Nair, 
S., Gray, G.K., Berbari, N.F., Bredel, M., Benveniste, E.N., Nozell, S.E., 2018. MicroRNA-31 is 
required for astrocyte specification. Glia. 
Mehler, M.F., 2008. Epigenetic principles and mechanisms underlying nervous system functions in health 
and disease. Progress in neurobiology 86, 305-341. 
Michelucci, A., Bithell, A., Burney, M.J., Johnston, C.E., Wong, K.Y., Teng, S.W., Desai, J., Gumbleton, N., 
Anderson, G., Stanton, L.W., Williams, B.P., Buckley, N.J., 2016. The Neurogenic Potential of 
Astrocytes Is Regulated by Inflammatory Signals. Molecular neurobiology 53, 3724-3739. 
Miska, E.A., Alvarez-Saavedra, E., Townsend, M., Yoshii, A., Sestan, N., Rakic, P., Constantine-Paton, M., 
Horvitz, H.R., 2004. Microarray analysis of microRNA expression in the developing mammalian 
brain. Genome biology 5, R68. 
Moller, H.G., Rasmussen, A.P., Andersen, H.H., Johnsen, K.B., Henriksen, M., Duroux, M., 2013. A 
systematic review of microRNA in glioblastoma multiforme: micro-modulators in the 
mesenchymal mode of migration and invasion. Molecular neurobiology 47, 131-144. 
Molne, M., Studer, L., Tabar, V., Ting, Y.T., Eiden, M.V., McKay, R.D., 2000. Early cortical precursors do not 
undergo LIF-mediated astrocytic differentiation. Journal of neuroscience research 59, 301-311. 
Molofsky, A.V., Krencik, R., Ullian, E.M., Tsai, H.H., Deneen, B., Richardson, W.D., Barres, B.A., Rowitch, 
D.H., 2012. Astrocytes and disease: a neurodevelopmental perspective. Genes & development 26, 
891-907. 
Morita, S., Noguchi, H., Horii, T., Nakabayashi, K., Kimura, M., Okamura, K., Sakai, A., Nakashima, H., Hata, 
K., Nakashima, K., Hatada, I., 2016. Targeted DNA demethylation in vivo using dCas9-peptide 
repeat and scFv-TET1 catalytic domain fusions. Nature biotechnology 34, 1060-1065. 
Murao, N., Noguchi, H., Nakashima, K., 2016. Epigenetic regulation of neural stem cell property from 
embryo to adult. Neuroepigenetics 5, 1-10. 
Myer, D.J., Gurkoff, G.G., Lee, S.M., Hovda, D.A., Sofroniew, M.V., 2006. Essential protective roles of 
reactive astrocytes in traumatic brain injury. Brain : a journal of neurology 129, 2761-2772. 
Naka-Kaneda, H., Nakamura, S., Igarashi, M., Aoi, H., Kanki, H., Tsuyama, J., Tsutsumi, S., Aburatani, H., 
Shimazaki, T., Okano, H., 2014. The miR-17/106-p38 axis is a key regulator of the neurogenic-to-
gliogenic transition in developing neural stem/progenitor cells. Proceedings of the National 
Academy of Sciences of the United States of America 111, 1604-1609. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
61 
 
Naka, H., Nakamura, S., Shimazaki, T., Okano, H., 2008. Requirement for COUP-TFI and II in the temporal 
specification of neural stem cells in CNS development. Nature neuroscience 11, 1014-1023. 
Nakamura, M., Yonekawa, Y., Kleihues, P., Ohgaki, H., 2001. Promoter hypermethylation of the RB1 gene 
in glioblastomas. Laboratory investigation; a journal of technical methods and pathology 81, 77-
82. 
Nakashima, K., Yanagisawa, M., Arakawa, H., Kimura, N., Hisatsune, T., Kawabata, M., Miyazono, K., Taga, 
T., 1999. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science 
284, 479-482. 
Namihira, M., Kohyama, J., Semi, K., Sanosaka, T., Deneen, B., Taga, T., Nakashima, K., 2009. Committed 
neuronal precursors confer astrocytic potential on residual neural precursor cells. Developmental 
cell 16, 245-255. 
Namihira, M., Nakashima, K., Taga, T., 2004. Developmental stage dependent regulation of DNA 
methylation and chromatin modification in a immature astrocyte specific gene promoter. FEBS 
letters 572, 184-188. 
Nato, G., Caramello, A., Trova, S., Avataneo, V., Rolando, C., Taylor, V., Buffo, A., Peretto, P., Luzzati, F., 
2015. Striatal astrocytes produce neuroblasts in an excitotoxic model of Huntington's disease. 
Development 142, 840-845. 
Nedergaard, M., 1994. Direct signaling from astrocytes to neurons in cultures of mammalian brain cells. 
Science 263, 1768-1771. 
Nieto, M., Schuurmans, C., Britz, O., Guillemot, F., 2001. Neural bHLH genes control the neuronal versus 
glial fate decision in cortical progenitors. Neuron 29, 401-413. 
Niranjan, R., 2014. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of 
Parkinson's disease: focus on astrocytes. Molecular neurobiology 49, 28-38. 
Niu, W., Zang, T., Zou, Y., Fang, S., Smith, D.K., Bachoo, R., Zhang, C.L., 2013. In vivo reprogramming of 
astrocytes to neuroblasts in the adult brain. Nature cell biology 15, 1164-1175. 
Niwa, H., Burdon, T., Chambers, I., Smith, A., 1998. Self-renewal of pluripotent embryonic stem cells is 
mediated via activation of STAT3. Genes & development 12, 2048-2060. 
Noguchi, H., Kimura, A., Murao, N., Namihira, M., Nakashima, K., 2016a. Prenatal deletion of DNA 
methyltransferase 1 in neural stem cells impairs neurogenesis and causes anxiety-like behavior in 
adulthood. Neurogenesis 3, e1232679. 
Noguchi, H., Murao, N., Kimura, A., Matsuda, T., Namihira, M., Nakashima, K., 2016b. DNA 
Methyltransferase 1 Is Indispensable for Development of the Hippocampal Dentate Gyrus. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 36, 6050-6068. 
Noushmehr, H., Weisenberger, D.J., Diefes, K., Phillips, H.S., Pujara, K., Berman, B.P., Pan, F., Pelloski, C.E., 
Sulman, E.P., Bhat, K.P., Verhaak, R.G., Hoadley, K.A., Hayes, D.N., Perou, C.M., Schmidt, H.K., 
Ding, L., Wilson, R.K., Van Den Berg, D., Shen, H., Bengtsson, H., Neuvial, P., Cope, L.M., Buckley, 
J., Herman, J.G., Baylin, S.B., Laird, P.W., Aldape, K., Cancer Genome Atlas Research, N., 2010. 
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. 
Cancer cell 17, 510-522. 
O'Callaghan, J.P., Kelly, K.A., VanGilder, R.L., Sofroniew, M.V., Miller, D.B., 2014. Early activation of STAT3 
regulates reactive astrogliosis induced by diverse forms of neurotoxicity. PloS one 9, e102003. 
Oberheim, N.A., Wang, X., Goldman, S., Nedergaard, M., 2006. Astrocytic complexity distinguishes the 
human brain. Trends in neurosciences 29, 547-553. 
Okada, S., Nakamura, M., Katoh, H., Miyao, T., Shimazaki, T., Ishii, K., Yamane, J., Yoshimura, A., Iwamoto, 
Y., Toyama, Y., Okano, H., 2006. Conditional ablation of Stat3 or Socs3 discloses a dual role for 
reactive astrocytes after spinal cord injury. Nature medicine 12, 829-834. 
Okano, M., Bell, D.W., Haber, D.A., Li, E., 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential 
for de novo methylation and mammalian development. Cell 99, 247-257. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
62 
 
Ostrom, Q.T., Gittleman, H., Xu, J., Kromer, C., Wolinsky, Y., Kruchko, C., Barnholtz-Sloan, J.S., 2016. 
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in 
the United States in 2009-2013. Neuro-oncology 18, v1-v75. 
Palma, V., Lim, D.A., Dahmane, N., Sanchez, P., Brionne, T.C., Herzberg, C.D., Gitton, Y., Carleton, A., 
Alvarez-Buylla, A., Ruiz i Altaba, A., 2005. Sonic hedgehog controls stem cell behavior in the 
postnatal and adult brain. Development 132, 335-344. 
Parpura, V., Basarsky, T.A., Liu, F., Jeftinija, K., Jeftinija, S., Haydon, P.G., 1994. Glutamate-mediated 
astrocyte-neuron signalling. Nature 369, 744-747. 
Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.M., 
Gallia, G.L., Olivi, A., McLendon, R., Rasheed, B.A., Keir, S., Nikolskaya, T., Nikolsky, Y., Busam, D.A., 
Tekleab, H., Diaz, L.A., Jr., Hartigan, J., Smith, D.R., Strausberg, R.L., Marie, S.K., Shinjo, S.M., Yan, 
H., Riggins, G.J., Bigner, D.D., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., 
Velculescu, V.E., Kinzler, K.W., 2008. An integrated genomic analysis of human glioblastoma 
multiforme. Science 321, 1807-1812. 
Patel, N.A., Moss, L.D., Lee, J.Y., Tajiri, N., Acosta, S., Hudson, C., Parag, S., Cooper, D.R., Borlongan, C.V., 
Bickford, P.C., 2018. Long noncoding RNA MALAT1 in exosomes drives regenerative function and 
modulates inflammation-linked networks following traumatic brain injury. Journal of 
neuroinflammation 15, 204. 
Pavlou, M.A.S., Pinho, R., Paiva, I., Outeiro, T.F., 2017. The yin and yang of alpha-synuclein-associated 
epigenetics in Parkinson's disease. Brain : a journal of neurology 140, 878-886. 
Pekny, M., Nilsson, M., 2005. Astrocyte activation and reactive gliosis. Glia 50, 427-434. 
Pekny, M., Pekna, M., 2014. Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiological 
reviews 94, 1077-1098. 
Pellerin, L., Bouzier-Sore, A.K., Aubert, A., Serres, S., Merle, M., Costalat, R., Magistretti, P.J., 2007. 
Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 55, 1251-
1262. 
Pereira, J.D., Sansom, S.N., Smith, J., Dobenecker, M.W., Tarakhovsky, A., Livesey, F.J., 2010. Ezh2, the 
histone methyltransferase of PRC2, regulates the balance between self-renewal and 
differentiation in the cerebral cortex. Proceedings of the National Academy of Sciences of the 
United States of America 107, 15957-15962. 
Polakis, P., 2007. The many ways of Wnt in cancer. Current opinion in genetics & development 17, 45-51. 
Rajendran, G., Shanmuganandam, K., Bendre, A., Muzumdar, D., Goel, A., Shiras, A., 2011. Epigenetic 
regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas. Journal of neuro-
oncology 104, 483-494. 
Rao, K.V., Panickar, K.S., Jayakumar, A.R., Norenberg, M.D., 2005. Astrocytes protect neurons from 
ammonia toxicity. Neurochemical research 30, 1311-1318. 
Raz, R., Lee, C.K., Cannizzaro, L.A., d'Eustachio, P., Levy, D.E., 1999. Essential role of STAT3 for embryonic 
stem cell pluripotency. Proceedings of the National Academy of Sciences of the United States of 
America 96, 2846-2851. 
Restrepo, A., Smith, C.A., Agnihotri, S., Shekarforoush, M., Kongkham, P.N., Seol, H.J., Northcott, P., Rutka, 
J.T., 2011. Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human 
malignant gliomas. Neuro-oncology 13, 42-50. 
Rheinbay, E., Suva, M.L., Gillespie, S.M., Wakimoto, H., Patel, A.P., Shahid, M., Oksuz, O., Rabkin, S.D., 
Martuza, R.L., Rivera, M.N., Louis, D.N., Kasif, S., Chi, A.S., Bernstein, B.E., 2013. An aberrant 
transcription factor network essential for Wnt signaling and stem cell maintenance in 
glioblastoma. Cell reports 3, 1567-1579. 
Rivetti di Val Cervo, P., Romanov, R.A., Spigolon, G., Masini, D., Martin-Montanez, E., Toledo, E.M., La 
Manno, G., Feyder, M., Pifl, C., Ng, Y.H., Sanchez, S.P., Linnarsson, S., Wernig, M., Harkany, T., 
AC
CE
PT
ED
 
AN
US
C
IPT
Pavlou et al.  Progress in Neurobiology 
63 
 
Fisone, G., Arenas, E., 2017. Induction of functional dopamine neurons from human astrocytes in 
vitro and mouse astrocytes in a Parkinson's disease model. Nature biotechnology 35, 444-452. 
Rothstein, J.D., Dykes-Hoberg, M., Pardo, C.A., Bristol, L.A., Jin, L., Kuncl, R.W., Kanai, Y., Hediger, M.A., 
Wang, Y., Schielke, J.P., Welty, D.F., 1996. Knockout of glutamate transporters reveals a major 
role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675-686. 
Sahni, V., Mukhopadhyay, A., Tysseling, V., Hebert, A., Birch, D., McGuire, T.L., Stupp, S.I., Kessler, J.A., 
2010. BMPR1a and BMPR1b signaling exert opposing effects on gliosis after spinal cord injury. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 30, 1839-1855. 
Sanosaka, T., Imamura, T., Hamazaki, N., Chai, M., Igarashi, K., Ideta-Otsuka, M., Miura, F., Ito, T., Fujii, N., 
Ikeo, K., Nakashima, K., 2017. DNA Methylome Analysis Identifies Transcription Factor-Based 
Epigenomic Signatures of Multilineage Competence in Neural Stem/Progenitor Cells. Cell reports 
20, 2992-3003. 
Schachtrup, C., Ryu, J.K., Helmrick, M.J., Vagena, E., Galanakis, D.K., Degen, J.L., Margolis, R.U., 
Akassoglou, K., 2010. Fibrinogen triggers astrocyte scar formation by promoting the availability of 
active TGF-beta after vascular damage. The Journal of neuroscience : the official journal of the 
Society for Neuroscience 30, 5843-5854. 
Scholze, A.R., Foo, L.C., Mulinyawe, S., Barres, B.A., 2014. BMP signaling in astrocytes downregulates EGFR 
to modulate survival and maturation. PloS one 9, e110668. 
Schreiner, B., Romanelli, E., Liberski, P., Ingold-Heppner, B., Sobottka-Brillout, B., Hartwig, T., 
Chandrasekar, V., Johannssen, H., Zeilhofer, H.U., Aguzzi, A., Heppner, F., Kerschensteiner, M., 
Becher, B., 2015. Astrocyte Depletion Impairs Redox Homeostasis and Triggers Neuronal Loss in 
the Adult CNS. Cell reports 12, 1377-1384. 
See, J., Mamontov, P., Ahn, K., Wine-Lee, L., Crenshaw, E.B., 3rd, Grinspan, J.B., 2007. BMP signaling 
mutant mice exhibit glial cell maturation defects. Molecular and cellular neurosciences 35, 171-
182. 
Sempere, L.F., Freemantle, S., Pitha-Rowe, I., Moss, E., Dmitrovsky, E., Ambros, V., 2004. Expression 
profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible 
roles in murine and human neuronal differentiation. Genome biology 5, R13. 
Setoguchi, T., Nakashima, K., Takizawa, T., Yanagisawa, M., Ochiai, W., Okabe, M., Yone, K., Komiya, S., 
Taga, T., 2004. Treatment of spinal cord injury by transplantation of fetal neural precursor cells 
engineered to express BMP inhibitor. Experimental neurology 189, 33-44. 
Sharif, A., Legendre, P., Prevot, V., Allet, C., Romao, L., Studler, J.M., Chneiweiss, H., Junier, M.P., 2007. 
Transforming growth factor alpha promotes sequential conversion of mature astrocytes into 
neural progenitors and stem cells. Oncogene 26, 2695-2706. 
Sher, F., Boddeke, E., Copray, S., 2011. Ezh2 expression in astrocytes induces their dedifferentiation 
toward neural stem cells. Cellular reprogramming 13, 1-6. 
Shimada, I.S., LeComte, M.D., Granger, J.C., Quinlan, N.J., Spees, J.L., 2012. Self-renewal and 
differentiation of reactive astrocyte-derived neural stem/progenitor cells isolated from the 
cortical peri-infarct area after stroke. The Journal of neuroscience : the official journal of the 
Society for Neuroscience 32, 7926-7940. 
Siddique, A.N., Nunna, S., Rajavelu, A., Zhang, Y., Jurkowska, R.Z., Reinhardt, R., Rots, M.G., Ragozin, S., 
Jurkowski, T.P., Jeltsch, A., 2013. Targeted methylation and gene silencing of VEGF-A in human 
cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA 
methylation activity. Journal of molecular biology 425, 479-491. 
Sirko, S., Behrendt, G., Johansson, P.A., Tripathi, P., Costa, M., Bek, S., Heinrich, C., Tiedt, S., Colak, D., 
Dichgans, M., Fischer, I.R., Plesnila, N., Staufenbiel, M., Haass, C., Snapyan, M., Saghatelyan, A., 
Tsai, L.H., Fischer, A., Grobe, K., Dimou, L., Gotz, M., 2013. Reactive glia in the injured brain acquire 
stem cell properties in response to sonic hedgehog. [corrected]. Cell stem cell 12, 426-439. 
AC
CE
PT
ED
 
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
64 
 
Sloan, S.A., Barres, B.A., 2014. Mechanisms of astrocyte development and their contributions to 
neurodevelopmental disorders. Current opinion in neurobiology 27, 75-81. 
Smirnova, L., Grafe, A., Seiler, A., Schumacher, S., Nitsch, R., Wulczyn, F.G., 2005. Regulation of miRNA 
expression during neural cell specification. The European journal of neuroscience 21, 1469-1477. 
Sofroniew, M.V., 2009. Molecular dissection of reactive astrogliosis and glial scar formation. Trends in 
neurosciences 32, 638-647. 
Sofroniew, M.V., Vinters, H.V., 2010. Astrocytes: biology and pathology. Acta neuropathologica 119, 7-35. 
Song, M.R., Ghosh, A., 2004. FGF2-induced chromatin remodeling regulates CNTF-mediated gene 
expression and astrocyte differentiation. Nature neuroscience 7, 229-235. 
Song, S., Kong, X., Acosta, S., Sava, V., Borlongan, C., Sanchez-Ramos, J., 2016. Granulocyte colony-
stimulating factor promotes behavioral recovery in a mouse model of traumatic brain injury. 
Journal of neuroscience research 94, 409-423. 
Sriram, K., Benkovic, S.A., Hebert, M.A., Miller, D.B., O'Callaghan, J.P., 2004. Induction of gp130-related 
cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial 
fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of 
neurodegeneration: key signaling pathway for astrogliosis in vivo? The Journal of biological 
chemistry 279, 19936-19947. 
Sudo, G., Kagawa, T., Kokubu, Y., Inazawa, J., Taga, T., 2016. Increase in GFAP-positive astrocytes in histone 
demethylase GASC1/KDM4C/JMJD2C hypomorphic mutant mice. Genes to cells : devoted to 
molecular & cellular mechanisms 21, 218-225. 
Sun, X., Liu, J., Xu, C., Tang, S.C., Ren, H., 2016. The insights of Let-7 miRNAs in oncogenesis and stem cell 
potency. Journal of cellular and molecular medicine 20, 1779-1788. 
Sun, Y., Nadal-Vicens, M., Misono, S., Lin, M.Z., Zubiaga, A., Hua, X., Fan, G., Greenberg, M.E., 2001. 
Neurogenin promotes neurogenesis and inhibits glial differentiation by independent mechanisms. 
Cell 104, 365-376. 
Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L.M., Liu, D.R., 
Aravind, L., Rao, A., 2009. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in 
mammalian DNA by MLL partner TET1. Science 324, 930-935. 
Tajiri, N., Acosta, S.A., Shahaduzzaman, M., Ishikawa, H., Shinozuka, K., Pabon, M., Hernandez-Ontiveros, 
D., Kim, D.W., Metcalf, C., Staples, M., Dailey, T., Vasconcellos, J., Franyuti, G., Gould, L., Patel, N., 
Cooper, D., Kaneko, Y., Borlongan, C.V., Bickford, P.C., 2014. Intravenous transplants of human 
adipose-derived stem cell protect the brain from traumatic brain injury-induced 
neurodegeneration and motor and cognitive impairments: cell graft biodistribution and soluble 
factors in young and aged rats. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 34, 313-326. 
Takizawa, T., Nakashima, K., Namihira, M., Ochiai, W., Uemura, A., Yanagisawa, M., Fujita, N., Nakao, M., 
Taga, T., 2001. DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation 
in the fetal brain. Developmental cell 1, 749-758. 
Takouda, J., Katada, S., Nakashima, K., 2017. Emerging mechanisms underlying astrogenesis in the 
developing mammalian brain. Proc Jpn Acad Ser B Phys Biol Sci 93, 386-398. 
Tan, S.L., Nishi, M., Ohtsuka, T., Matsui, T., Takemoto, K., Kamio-Miura, A., Aburatani, H., Shinkai, Y., 
Kageyama, R., 2012. Essential roles of the histone methyltransferase ESET in the epigenetic 
control of neural progenitor cells during development. Development 139, 3806-3816. 
Tao, J., Wu, H., Lin, Q., Wei, W., Lu, X.H., Cantle, J.P., Ao, Y., Olsen, R.W., Yang, X.W., Mody, I., Sofroniew, 
M.V., Sun, Y.E., 2011. Deletion of astroglial Dicer causes non-cell-autonomous neuronal 
dysfunction and degeneration. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 31, 8306-8319. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
65 
 
Taylor, M.K., Yeager, K., Morrison, S.J., 2007. Physiological Notch signaling promotes gliogenesis in the 
developing peripheral and central nervous systems. Development 134, 2435-2447. 
Tessarz, P., Kouzarides, T., 2014. Histone core modifications regulating nucleosome structure and 
dynamics. Nature reviews. Molecular cell biology 15, 703-708. 
Tian, W., Sawyer, A., Kocaoglu, F.B., Kyriakides, T.R., 2011. Astrocyte-derived thrombospondin-2 is critical 
for the repair of the blood-brain barrier. The American journal of pathology 179, 860-868. 
Torper, O., Pfisterer, U., Wolf, D.A., Pereira, M., Lau, S., Jakobsson, J., Bjorklund, A., Grealish, S., Parmar, 
M., 2013. Generation of induced neurons via direct conversion in vivo. Proceedings of the National 
Academy of Sciences of the United States of America 110, 7038-7043. 
Tsuyama, J., Bunt, J., Richards, L.J., Iwanari, H., Mochizuki, Y., Hamakubo, T., Shimazaki, T., Okano, H., 
2015. MicroRNA-153 Regulates the Acquisition of Gliogenic Competence by Neural Stem Cells. 
Stem cell reports 5, 365-377. 
Tu, Z., Li, Y., Dai, Y., Li, L., Lv, G., Chen, I., Wang, B., 2017. MiR-140/BDNF axis regulates normal human 
astrocyte proliferation and LPS-induced IL-6 and TNF-alpha secretion. Biomedicine & 
pharmacotherapy = Biomedecine & pharmacotherapie 91, 899-905. 
Tulina, N., Matunis, E., 2001. Control of stem cell self-renewal in Drosophila spermatogenesis by JAK-STAT 
signaling. Science 294, 2546-2549. 
Turcan, S., Makarov, V., Taranda, J., Wang, Y., Fabius, A.W.M., Wu, W., Zheng, Y., El-Amine, N., Haddock, 
S., Nanjangud, G., LeKaye, H.C., Brennan, C., Cross, J., Huse, J.T., Kelleher, N.L., Osten, P., 
Thompson, C.B., Chan, T.A., 2018. Mutant-IDH1-dependent chromatin state reprogramming, 
reversibility, and persistence. Nature genetics 50, 62-72. 
Turcan, S., Rohle, D., Goenka, A., Walsh, L.A., Fang, F., Yilmaz, E., Campos, C., Fabius, A.W., Lu, C., Ward, 
P.S., Thompson, C.B., Kaufman, A., Guryanova, O., Levine, R., Heguy, A., Viale, A., Morris, L.G., 
Huse, J.T., Mellinghoff, I.K., Chan, T.A., 2012. IDH1 mutation is sufficient to establish the glioma 
hypermethylator phenotype. Nature 483, 479-483. 
Venneti, S., Garimella, M.T., Sullivan, L.M., Martinez, D., Huse, J.T., Heguy, A., Santi, M., Thompson, C.B., 
Judkins, A.R., 2013. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of 
Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A 
K27M mutant glioblastomas. Brain pathology 23, 558-564. 
Vojta, A., Dobrinic, P., Tadic, V., Bockor, L., Korac, P., Julg, B., Klasic, M., Zoldos, V., 2016. Repurposing the 
CRISPR-Cas9 system for targeted DNA methylation. Nucleic acids research 44, 5615-5628. 
Voskuhl, R.R., Peterson, R.S., Song, B., Ao, Y., Morales, L.B., Tiwari-Woodruff, S., Sofroniew, M.V., 2009. 
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune 
inflammation of the CNS. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 29, 11511-11522. 
Wang, C.Y., Yang, S.H., Tzeng, S.F., 2015. MicroRNA-145 as one negative regulator of astrogliosis. Glia 63, 
194-205. 
Wang, T., Pan, Q., Lin, L., Szulwach, K.E., Song, C.X., He, C., Wu, H., Warren, S.T., Jin, P., Duan, R., Li, X., 
2012. Genome-wide DNA hydroxymethylation changes are associated with neurodevelopmental 
genes in the developing human cerebellum. Human molecular genetics 21, 5500-5510. 
Weller, M., Stupp, R., Reifenberger, G., Brandes, A.A., van den Bent, M.J., Wick, W., Hegi, M.E., 2010. 
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature 
reviews. Neurology 6, 39-51. 
Wilhelmsson, U., Bushong, E.A., Price, D.L., Smarr, B.L., Phung, V., Terada, M., Ellisman, M.H., Pekny, M., 
2006. Redefining the concept of reactive astrocytes as cells that remain within their unique 
domains upon reaction to injury. Proceedings of the National Academy of Sciences of the United 
States of America 103, 17513-17518. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
66 
 
Williams, M.J., Singleton, W.G., Lowis, S.P., Malik, K., Kurian, K.M., 2017. Therapeutic Targeting of Histone 
Modifications in Adult and Pediatric High-Grade Glioma. Frontiers in oncology 7, 45. 
Wu, H., Coskun, V., Tao, J., Xie, W., Ge, W., Yoshikawa, K., Li, E., Zhang, Y., Sun, Y.E., 2010. Dnmt3a-
dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 
329, 444-448. 
Xiao, Q., Du, Y., Wu, W., Yip, H.K., 2010. Bone morphogenetic proteins mediate cellular response and, 
together with Noggin, regulate astrocyte differentiation after spinal cord injury. Experimental 
neurology 221, 353-366. 
Xu, N., Papagiannakopoulos, T., Pan, G., Thomson, J.A., Kosik, K.S., 2009. MicroRNA-145 regulates OCT4, 
SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137, 647-658. 
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Wang, P., Xiao, M.T., Liu, L.X., Jiang, 
W.Q., Liu, J., Zhang, J.Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.H., Lei, Q.Y., Guan, K.L., Zhao, S.M., 
Xiong, Y., 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-
ketoglutarate-dependent dioxygenases. Cancer cell 19, 17-30. 
Xu, X., Tao, Y., Gao, X., Zhang, L., Li, X., Zou, W., Ruan, K., Wang, F., Xu, G.L., Hu, R., 2016. A CRISPR-based 
approach for targeted DNA demethylation. Cell discovery 2, 16009. 
Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., 
Riggins, G.J., Friedman, H., Friedman, A., Reardon, D., Herndon, J., Kinzler, K.W., Velculescu, V.E., 
Vogelstein, B., Bigner, D.D., 2009. IDH1 and IDH2 mutations in gliomas. The New England journal 
of medicine 360, 765-773. 
Yang, C.H., Yue, J., Pfeffer, S.R., Fan, M., Paulus, E., Hosni-Ahmed, A., Sims, M., Qayyum, S., Davidoff, A.M., 
Handorf, C.R., Pfeffer, L.M., 2014. MicroRNA-21 promotes glioblastoma tumorigenesis by down-
regulating insulin-like growth factor-binding protein-3 (IGFBP3). The Journal of biological 
chemistry 289, 25079-25087. 
Yang, H., Feng, G.D., Olivera, C., Jiao, X.Y., Vitale, A., Gong, J., You, S.W., 2012. Sonic hedgehog released 
from scratch-injured astrocytes is a key signal necessary but not sufficient for the astrocyte de-
differentiation. Stem cell research 9, 156-166. 
Yin, D., Xie, D., Hofmann, W.K., Miller, C.W., Black, K.L., Koeffler, H.P., 2002. Methylation, expression, and 
mutation analysis of the cell cycle control genes in human brain tumors. Oncogene 21, 8372-8378. 
Yu, J., Zhang, H., Gu, J., Lin, S., Li, J., Lu, W., Wang, Y., Zhu, J., 2004. Methylation profiles of thirty four 
promoter-CpG islands and concordant methylation behaviours of sixteen genes that may 
contribute to carcinogenesis of astrocytoma. BMC cancer 4, 65. 
Zador, Z., Stiver, S., Wang, V., Manley, G.T., 2009. Role of aquaporin-4 in cerebral edema and stroke. 
Handbook of experimental pharmacology, 159-170. 
Zamanian, J.L., Xu, L., Foo, L.C., Nouri, N., Zhou, L., Giffard, R.G., Barres, B.A., 2012. Genomic analysis of 
reactive astrogliosis. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 32, 6391-6410. 
Zhang, K., Wang, X.Q., Zhou, B., Zhang, L., 2013. The prognostic value of MGMT promoter methylation in 
Glioblastoma multiforme: a meta-analysis. Familial cancer 12, 449-458. 
Zhang, L., He, X., Liu, L., Jiang, M., Zhao, C., Wang, H., He, D., Zheng, T., Zhou, X., Hassan, A., Ma, Z., Xin, 
M., Sun, Z., Lazar, M.A., Goldman, S.A., Olson, E.N., Lu, Q.R., 2016. Hdac3 Interaction with p300 
Histone Acetyltransferase Regulates the Oligodendrocyte and Astrocyte Lineage Fate Switch. 
Developmental cell 36, 316-330. 
Zhang, Y., Barres, B.A., 2010. Astrocyte heterogeneity: an underappreciated topic in neurobiology. Current 
opinion in neurobiology 20, 588-594. 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
67 
 
Figure legends 
 
Figure 1: Depiction of key epigenetic mechanisms. DNA methylation conducted by DNMTs 
results in the inability of transcription factors to bind to gene promoter regions or in the recruitment 
of repressor proteins. Both events contribute to gene repression. Conversely, DNA demethylation 
catalyzed by demethylases allows gene transcription. The major histone modifications include 
methylation (Me), acetylation (Ac), phosphorylation (P), ubiquitination (Ub) and sumoylation (S), 
influencing chromatin condensation and gene transcription both positively and negatively 
depending on the histone marks. Targeted mRNAs are recognized by miRNAs via sequence 
complementarity. The final result of this interaction involves the degradation of the mRNA target 
or the repression of its translation.   
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Figure 2: Examples of major transcriptional and epigenetic events driving gene expression 
of two main astrocytic markers, GFAP and S100b. In NSCs, GFAP promoter is highly 
methylated due to DNMT1 activity. In addition, ESET protein is responsible for the elevated 
trimethylation marks of histone H3K9. Also, the dimer RAR/RXR forms a complex with various 
co-repressors recruiting HDACs which maintain a closed chromatin structure, thus leading to the 
repression of GFAP expression. During late-gestation, Notch ligands expressed in cells determined 
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to become neurons bind to Notch protein of their neighboring NSCs. This binding induces 
proteolytic cleavage and release of the NICD, which enters the nucleus and binds to RBP-JK. The 
NICD/RBP-JK complex induces the expression of NFIA. MiR-153 targets NFIA mRNA inhibiting 
its translation. NFIA is able to bind to the GFAP promoter resulting in the removal of methyl 
groups (CH3) and in the dissociation of DNMT1. Further, ESET protein levels are reduced leading 
to decreased H3K9me3. Lastly, binding of RA to RAR/RXR dimer attracts transcriptional co-
activators, allowing the chromatin to obtain a relaxed structure through acetylation of histone H3. 
Upon these conformational changes, STAT3 is able to bind to the GFAP promoter recruiting the 
transcriptional co-activators CBP/p300. FGF2 additionally facilitates access of the STAT/CBP to 
the GFAP promoter, while also increases and decreases H3K4 methylation (H3K4met) and H3K9 
methylation (H3K9met) respectively. As a result, GFAP expression is induced and astroglial 
differentiation commences. Similarly to GFAP, the expression S100B is also repressed in early 
brain development.  This is due to promoter methylation and to the binding of MeCP2, which 
recruits HDACs and co-repressors to the promoter. In later stages, along astrocytic differentiation, 
promoter demethylation and decreased MeCP2 levels lead to the induction of S100B expression. 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Pavlou et al.  Progress in Neurobiology 
70 
 
 
 
Figure 3: Schematic illustration of specific transcriptional and epigenetic alterations during 
reactive astrogliosis. Under inflammatory conditions or in the presence of a lesion, several 
signaling pathways are activated. Binding of TNF to the cognate receptor allows the dissociation 
and degradation of IκΒ from the IκB/NF-κB complex. NF-κB is then released and translocates into 
the nucleus, where it will activate the transcription of key reactive astrocytic markers, such as 
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LCN2. Activation of the JAK/STAT pathway enables the phosphorylation of STAT3 and its 
subsequent translocation to the nucleus, which will induce the transcription of GFAP, LCN2 and 
potentially of miR-21 as well. In turn, LCN2 is able to further activate the JAK/STAT and NF-κB 
signaling pathways stimulating chemokine production and astrocyte migration. In addition, the 
JNK and MAPK/ERK pathways are activated and implicated in the induction of GFAP expression. 
MiR-21 levels are elevated in SCI and positively influence GFAP protein levels. In differentiated 
cells, the pluripotency factors OCT4, SOX2 and KLF-4 are not present due to miR-145 activity. 
However, reduced miR-145 levels in SCI may potentially reactivate the expression of these 
proteins, together with the translational activation of the suggested GFAP and MYC mRNA targets.  
In this way, reactive astrocytes obtain stem cell hallmarks. In addition, miR-181 is decreased upon 
inflammation and is no longer able to target and control the translation of MECP2 mRNA. Under 
physiological conditions, miR-140 inhibits BDNF translation and cell proliferation participating 
in astrocyte differentiation. However, inflammation results in miR-140 decrease and is associated 
with cell proliferation as well as acquisition of NSC characteristics.  
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